Budding_Trader (@BuddingTrader2) profile picture

LT Investor Taking Ginger Steps in to The Trading World Now

Joined March 2021
Photo by Budding_Trader (@BuddingTrader2)Photo by Budding_Trader (@BuddingTrader2)Photo by Budding_Trader (@BuddingTrader2)Photo by Budding_Trader (@BuddingTrader2)Photo by Budding_Trader (@BuddingTrader2)Photo by Budding_Trader (@BuddingTrader2)Photo by Budding_Trader (@BuddingTrader2)Photo by Budding_Trader (@BuddingTrader2)Photo by Budding_Trader (@BuddingTrader2)
Budding_Trader retweeted
Nifty 39k or 18k!!! Bullish perspective out of last 10 quarter earnings More or less earnings were stagnant for 5-6 qtrs and then Q3 FY26 showed some green shoots Q4 FY26 validated them And then Q1FY27 --weakest qtr historically showed amazing earnings and Q2 Fy27 stamped it further if Q3 and Q4 FY27 matches and grows (ideally it should as H2 is more heavy). Bull mkt may be just starting Nifty returns anyway are less than earnings over last 6-7 years and it has to catch up Private capex started happening Add to that Trade deals from NZ, Europe Add to that trade deals from US might happen Thats on bullish side Now coming to bearish perspective Few things there!! If H2 FY27 goes for a toss or Margin compression further deepens, then we are going down but not too much I believe (ofc i can go wrong in estimations) Another disaster could be coming UP elections US trade deal not happening as per Indian liking Crude stays above 100 for long USD Move towards 100 and stays between 95-105 Promoters keep selling/diluting All this leads to bearish scenario What is my Bull case! 37000-39000 on Nifty by March 28 (discussed with many people in Jan2026, March26 and so on) What is my bearish case 18000-19000 on Nifty by June28 But if 38K on nifty comes first then downside may be limited to 25K on nifty by June28-sep28 Please take above analysis with pinch of salt I can go wrong like many times in the past and mind it I am more of bullish person than bearish so may have given more weightage to bullish scenraio I may have missed some critical elements in analysis ➕ as situations and facts change, I need to revisit and change my understanding so nothing is written in stone Its just a probability its just a broad view #Nifty50
5
4
44
3,945
Budding_Trader retweeted
Timepass talk on Sunday 1. Namo eWaste Management Namo eWaste Management is an integrated e-waste and lithium-ion battery recycling company with four plants, 26+ collection centres and 300+ clients. Its revenue streams include e-waste recycling, refurbishment of electronic devices, EPR credits and compliance services, and battery recycling. It recovers valuable materials such as copper, aluminium, gold and silver while extending the life of usable electronics. In FY26, revenue grew 29% to ₹195 crore, EBITDA increased 56% to ₹23.1 crore and PAT grew 70% to ₹14.35 crore, reflecting operating efficiencies and improving profitability. The key opportunity is its planned move up the value chain through hydrometallurgy. Instead of stopping at producing black mass from used lithium-ion batteries, the company intends to recover critical minerals such as lithium, cobalt, nickel and manganese, potentially creating a higher-margin business. Near-term triggers include the ramp-up of its Nashik battery recycling facility, commissioning of the Hyderabad plant to improve access to South India's electronics ecosystem and reduce logistics costs, and higher utilisation of existing capacity. Stricter EPR compliance, rising e-waste generation and growing demand for critical minerals provide additional structural tailwinds. Management is targeting approximately ₹400 crore revenue in FY27, comprising ₹200–210 crore from e-waste and around ₹200 crore from battery-related operations. It expects battery recycling EBITDA margins of approximately 20%, while the proposed hydrometallurgy business could generate 25–30% margins after black-mass recovery. Management also indicated an aspiration to roughly double FY26 PAT of ₹14.35 crore, subject to successful execution. The hydrometallurgy project is planned in phases, beginning with a pilot facility before scaling up; government subsidies are expected to support the investment. Management has also indicated a potential main-board migration in 1.5–2 years, subject to reaching revenue of ₹800–900 crore and PAT above ₹50 crore. 2. Innomet Advanced Materials Innomet Advanced is a specialty powder metallurgy company operating through two divisions: metal/alloy powders and tungsten heavy alloys (THA). Its metal powders cater to automotive components, diamond tools, coatings, catalysts and additive manufacturing, while tungsten heavy alloys find applications in defence, aerospace, radiation shielding and engineering. Innomet's key differentiation is its specialised materials expertise and position in niche tungsten heavy alloys, including defence applications such as Pinaka rocket pre-fragments. The company received AS9100D aerospace certification, strengthening its access to global aerospace and defence supply chains. Its acquisition of a 57.5% stake in Swastik Tungsten provides backward integration and opens a new business in tungsten metal powders, tungsten carbide powders and components. Another important trigger is its DRDO-supported collaboration with IIT Hyderabad to establish an advanced gas atomisation facility for aerospace, defence and additive manufacturing powders, with a sanctioned project outlay of ₹8.73 crore. Export growth, China+1 opportunities and new product commercialisation are additional potential catalysts. Per the FY26 concall, management were expecting the metal powders division to reach its existing capacity limit soon, with plans to expand from 50 tonnes per month towards 75–100 tonnes. This is something that needs to be tracked in H1 commentary. Tungsten heavy alloy capacity has increased to 5 tonnes per month, with management indicating around 50% utilisation. Innomet’s international order book has exploded in FY27, driven by strong traction in tungsten heavy alloys, particularly from Israel. This could translate into not just stunning revenue growth but also a sharp improvement in margins, with management expecting THA EBITDA margins to exceed 20%. If execution remains on track, FY27 revenues could potentially more than double FY26 levels. 3. Oligonucleotides Think of our body as a factory that produces proteins to perform different functions. DNA is the master blueprint, and RNA carries the instructions to the factory on which proteins to make. But what happens when these instructions lead to the production of a harmful protein? Oligonucleotides are short, synthetic strands of DNA or RNA designed to intervene in this process. Some proteins are extremely difficult to target directly with conventional drugs. Instead of trying to catch the harmful protein after it is produced, oligonucleotides intercept the message that tells the body to make it. By blocking, destroying or modifying that message, they can reduce or alter the production of the target protein. Imagine intelligence agencies know terrorists are hiding in a town but cannot identify which houses they occupy. One approach is to search for them house by house, much like conventional small-molecule drugs (Aspirin or Dolo) that target proteins directly. But if that's not feasible or practical, the alternative is to intercept the messages carrying their instructions (from Terroristan) before they can act. That’s the oligonucleotide approach: instead of targeting the culprit, intercept the message that tells the body to produce it. This ability to intervene at the level of genetic instructions opens up possibilities for treating diseases that were previously difficult to address with conventional medicines. Some oligonucleotide therapies can also deliver long-lasting effects, allowing less frequent dosing, depending on the drug. For the CDMO industry, this creates a specialised manufacturing opportunity. Oligonucleotides require expertise in complex chemical synthesis, purification and quality control. As more therapies advance towards commercialisation, specialist CDMOs could benefit from growing demand for outsourced manufacturing. In the CDMO universe, Oligonucleotides are expected to grow at 20% CAGR. Within the Indian CDMO universe, Cohance Life (thru Sapala Organics), Sai Life, and Anthem Bio talked about Oligos but it is still an evolving area. 4. Kanohar Electricals Kanohar is a 54-year-old engineering company specialising in high-voltage power transformers, railway transformers and shunt reactors, with an EPC business covering substations and transmission lines. Transformers contributed around 85% of FY26 revenue, while EPC accounted for the remaining 15%. The company operates manufacturing facilities in Meerut with a combined annual capacity of 19,200 MVA and reported FY26 revenue of ₹653.8 crore with an EBITDA margin of 27.6%. The key differentiator is its qualification-led position in high-voltage transformers. Large utility and railway tenders require proven field performance and product-specific short-circuit certification, which can take 18–24 months to obtain. Kanohar has completed over 200 successful short-circuit tests and is among the few Indian manufacturers certified for 500 MVA, 400 kV transformers. Its 400 kV product contribution rose from 10.3% of transformer revenue in FY24 to 52% in FY26 and approximately 70% in Q1 FY27, reflecting a shift towards higher-value products. The industry opportunity is supported by structural demand from rising electricity consumption, renewable-energy evacuation, data centres and railway modernisation. The government’s Green Energy Corridor III, with a stated outlay of ₹1.85 lakh crore, is focused on intra-state transmission, where 400 kV equipment is particularly relevant. Kanohar also has a potential longer-term growth lever in 765 kV transformers, although management indicated that regular tender eligibility could take another three to four years. Management is targeting FY27 revenue of approximately ₹950 crore (45% YoY growth), with an EBITDA margin broadly similar to FY26’s 27.6%. The June-end order book stood at ₹2,026 crore, with another ₹867.3 crore of orders added during Q2. The company plans an additional 18,000 MVA of capacity at Gangol for FY29, while its roughly 120-day net working-capital cycle remains an important factor to monitor. 5. RBZ Jewellers - Shared on multiple times in last 10 months Below is the original post followed the latest update RBZ Jewellers operates a unique dual-channel model, combining a strong B2B wholesale presence, supplying to national giants like Titan, Malabar and PNG, with its high-growth B2C retail brand, Harit Zaveri Jewellers, which currently operates an ~11,000 sq. ft. flagship store in Ahmedabad. A little over a year ago, RBZ had guided for ₹800 crore revenue in FY26 and ₹1,000 crore in FY27. During the Q4FY25 concall, the FY26 guidance was moderated to ₹700 crore, while FY27 guidance of ₹1,000 crore was retained. However, in the Q3FY26 concall, management further revised expectations, guiding for ₹630–650 crore in FY26 and ₹800–900 crore in FY27. With multiple factors coming together (guidance coming down, volumes coming down), the market seems to have lost interest in the stock, pushing valuations to what appears to be their cheapest levels so far. But there may be a silver lining. The company is on track to open two large retail stores in Surat and Rajkot by Q2FY27. If executed well, these three stores could potentially push retail revenues into four digits, while also improving overall margins. That said, in the near term PAT may remain under pressure, as marketing spends and other launch-related expenses could weigh on profitability in FY27. Structurally, the business mix is also evolving. By FY27, volumes are expected to be roughly split 50:50 between retail and B2B, while retail could contribute ~75% of revenues, with wholesale and job work accounting for the remaining ~25%. Latest update: FY26 ended with 636cr revenue with 15% margins and Q1 posted 120cr revenues with ~15% EBITDA margins. However, the more interesting development is on the B2C front! The company opened its second retail outlet in September, a 10,000 sq. ft. flagship store in Surat, with couple of more stores in the pipeline. The B2C transformation is now becoming visible. Profitability may remain muted in FY27 due to promotional spending and working-capital requirements as the retail business scales up. However, if execution stays on track, FY28 could be a substantially stronger year for profitability. What to track in Q2: Progress in the launch of new stores. Inventory and working capital trends. Promotional spending for newly launched stores and its impact on profitability. Progress of the daily wear product launch. Effectiveness of the company's hedging strategy in managing input cost volatility and protecting margins. That's all for this edition. Have a great Sunday! Disclaimer: None or buy or sell recommendations. This publicly available information is shared for learning and education purposes.
13
49
377
43,336
Budding_Trader retweeted
Timepass talk on Sunday 1. Ringa Ringa Roses The Subscription Model of War Russian crude goes to Indian refineries at a discount, comes out as diesel, and sails to Europe, where the paperwork has completed its spiritual rebirth. Europe uses the proceeds of its fuel bill to fund Ukraine, Ukraine fills its tanks from European suppliers whose diesel has an Indian grandparent, and India uses the margin to buy the next Russian barrel. Russia turns that revenue into missiles, Ukraine asks Europe for more money, and the loop renews. Every party is both customer and supplier, so nobody cancels. It is the first war with recurring revenue, and the only one where the retention strategy is the conflict itself. The diesel shock is getting harder to ignore. Before the Iran war, the US national-average diesel price was around $3.76/gallon. Today, it is around $6.4/gallon, roughly a 70% jump. Europe is facing a similar squeeze. The EU-average diesel price has risen from around €1.59/litre before the war to €2.24/litre now, a ~41% increase. India is an interesting contrast. While retail diesel prices have largely been kept in check, Delhi retail diesel is around ₹95/litre, bulk diesel has now surged to ₹153.57/litre, after a ₹14.60/litre increase. Bulk prices reflect international product benchmarks much more directly than the government-controlled retail pump prices. So, the pain hasn't disappeared in India. It has simply shifted from the retail pump to bulk consumers, transporters, industrial users and institutions. And that eventually has to show up somewhere: logistics costs, freight rates, margins and, ultimately, prices. The AI Money Carousel Nvidia invests in OpenAI, and OpenAI buys Nvidia chips. Microsoft invests in OpenAI, and OpenAI commits $250 billion to Azure. OpenAI signs a $300 billion compute deal with Oracle, and Oracle spends heavily on Nvidia's chips to deliver it. AMD hands OpenAI warrants for up to 160 million of its own shares so that OpenAI will buy AMD chips, while Nvidia puts about $2 billion into CoreWeave, which buys Nvidia GPUs. Amazon invests in Anthropic, which promises over $100 billion back to AWS. Each round trip is booked as revenue, the analysts applaud, and nobody has located the end customer, because a circle has no end to look for. It is the only business model where the money never leaves the building and everyone still calls it a "partnership". Disclaimer: This is just a sarcastic take and mayn't necessarily be 100% accurate. 2. Do Ankhen Barah Haath i) Humanoid Robotics The humanoid robotics sector is transitioning from controlled research laboratories into scalable industrial deployment, targeting a total addressable market (TAM) projected to expand from roughly $5.4 billion to over $50 billion by 2035. Early wealth creation is concentrated in structured manufacturing environments, particularly automotive assembly and heavy logistics, where general-purpose machines absorb the shock of shrinking domestic labor pools and rising operational overhead. As advanced spatial AI and mechanical actuators mature, the addressable pool will broaden significantly into hazardous operational fields like chemical processing, nuclear maintenance, and disaster response. Because enterprises view physical labor as a massive, recurring line-item expenditure, the widespread adoption of Hardware-as-a-Service (HaaS) subscription deployment models offers early technology providers and component manufacturers a predictable, high-margin pathway to compounding enterprise value. ii) Artificial Intelligence Artificial Intelligence serves as the primary cognitive infrastructure layer of the modern economy, with a soaring TAM expected to scale from roughly $900 billion toward $4.2 trillion to $8.7 trillion by 2035. While early market enthusiasm focused heavily on consumer-facing applications, long-term wealth creation is shifting aggressively toward enterprise software, autonomous agent architectures, and verticalized machine-learning models integrated into sensitive sectors like financial services, cybersecurity, and biopharmaceutical discovery. This software expansion creates a massive downstream derivative market for physical infrastructure, forcing unprecedented capital expenditure into advanced semiconductor manufacturing, high-density power grid transformers, and green baseload energy sources. Consequently, companies controlling proprietary domain-specific data and critical computational hardware sit at the center of the century's most lucrative value chain. 3. Tungsten: Small Volumes, Outsized Criticality Tungsten is a dense, hard, high-strength metal with the highest melting point of any metal (about 3,422°C), which makes it hard to substitute in extreme-heat, wear and high-density uses. It is a strategic input for cutting tools, defense, aerospace and semiconductors, yet roughly 80% of global supply sits in China, which has tightened exports since 2025. Tungsten's value rests on its density (close to gold's) and exceptional hardness, and two of its derivatives matter most commercially. The first is tungsten carbide, formed by combining tungsten powder with carbon. It has hardness approaching that of diamond and is usually sintered with a cobalt binder into cemented carbide. This is the largest end use, at roughly half or more of demand by most industry estimates, and it goes into cutting tool inserts, drill bits, mining and oil and gas tooling, dies and wear parts that underpin modern machining in autos, aerospace and general engineering. Cobalt is a second input in this chain, and carbide scrap recycling is a meaningful secondary source of tungsten. The second is tungsten hexafluoride, a gas made by reacting tungsten metal with fluorine. It is far smaller in volume but critical in semiconductors, where it is the precursor for chemical and atomic layer deposition of the thin tungsten films used for contacts, vias and plugs in logic chips and for wordlines in 3D NAND and DRAM. Ultra-high-purity WF₆ has no easy substitute in these processes, so chipmakers depend on a reliable supply of high-grade tungsten metal. Beyond these two, tungsten also goes into tool steels and superalloys, heavy alloys for defense, counterweights and radiation shielding, X-ray targets and filaments, and emerging uses such as fusion reactor components. The core supply chain problem is concentration combined with policy. China controls roughly 80% of global mine supply and dominates the downstream APT, powder and carbide chain, and imposed export licensing on tungsten in February 2025 after US tariffs on Chinese imports. It also cut mining quotas in 2025 and, in December 2025, said only 15 firms would be allowed to export tungsten in 2026–2027, which gives Beijing control over volume, timing and destination. Estimates of the cut in Chinese exports are around 40%, though that figure comes from secondary sources. The result has been a sharp repricing: APT prices were above $3,000 per metric ton in Rotterdam, up more than 200% since the start of that year. Western governments are adding to the tightness through restrictions on defense contractors sourcing from China and through stockpiling. New supply is slow to arrive. South Korea's Sangdong mine could go from zero output in 2025 to about 2,300 tonnes in 2026 and 4,600 tonnes from 2027, but greenfield projects generally take 5–10 years to reach commercial production, and S&P still projects an ex-China supply gap even after announced projects deliver. Even ore mined outside China often has to pass through Chinese-dominated refining and powder steps, so the midstream is as much a bottleneck as the mines. 4. Augmont Enterprises Augmont is India's only vertically integrated, technology-driven gold and silver platform operating across the full precious metals value chain, from procurement and refining to B2B bullion trading, digital gold, jewellery-on-EMI, and gold-backed lending. Incorporated in 2012 and headquartered in Mumbai, Augmont serves 5,223+ enterprise members (jewellers, bullion dealers, manufacturers) through its 'Augmont SPOT' OTC platform and 49.62 million retail consumers through its 'Augmont Gold For All' digital platform. The company operates two refineries (Rudrapur, UP and Navi Mumbai; combined capacity 284 MT/year) and a jewellery SEZ unit in Jaipur. Think of Augmont as a very large middleman for gold and silver that earns a tiny slice on each transaction, but handles an enormous amount of metal. 1. Selling to jewellers (about 87% of revenue). Jewellers and bullion dealers place orders on Augmont's platform (SPOT) at live prices. Augmont instantly buys the same metal from a bank, a refinery or scrap sellers, then sells it on to the jeweller. Because the buy and sell are matched within seconds, it carries little price risk and keeps a spread of roughly 0.25-0.45% of the value. On ₹81,700 Cr of volume, that adds up. Revenue looks huge (₹94,186 Cr) because it counts the full value of the gold sold, but the actual profit margin is under 0.5%. 2. Buying gold cheaper than others. Augmont imports "doré" bars, which are impure gold, at a 0.65% lower import duty than pure gold, then refines them in its own plants. This saved it about ₹76 Cr in FY26. 3. Selling to ordinary people. On its Gold For All app, people buy small amounts of digital gold or silver, start monthly savings plans, buy coins, or pay for jewellery in monthly instalments. Augmont earns a small margin on each sale. It also facilitates gold loans through a group company and buys old gold from households. 4. Interest and treasury income. Part of its profit comes from "other income" on cash and investments rather than from selling gold. That was ₹96 Cr of its ₹473 Cr pre-tax profit in FY26. The business works only at high volume, and it needs a lot of cash to stock gold, which is why it raised equity from the IPO. What's in store? Shift from jewellery to investment gold. The report cites WGC data showing investment demand (82t) overtook jewellery (66t) for the first time since 2000 in Jan-Mar 2026. Digital gold UPI transactions tripled to ₹17,631 Cr in H1 2026, and gold ETF AUM is going from ~₹42k Cr to ₹65k Cr+. Augmont sits in every channel: ETF authorised participant, digital gold, coins and bars, and NSE's EGR fulfilment. SPOT scale-up. It adds 15 delivery centres by FY29 (from 20 across 13 states) to reach Tier 3/4 jewellers. The platform earns 25-45 bps spreads on ₹81,700 Cr of volume. Formalisation helps, since the organised share of the bullion market is ~30% and is projected to reach ~50% by 2030E. Jewellery-on-EMI. Customers pre-book at ₹500-1,000 a month. FY26 revenue was ₹845 Cr, a 57% two-year CAGR, with 106 Gold For All stores expanding into Tier 3/4 markets. Refinery operating leverage. Capacity is 284 MT but only 13.34 MT was refined in FY26 (4.7% utilisation). Lab-grown diamonds, gold loans, silver, recycled gold and old-gold buyback through the stores can all run on the existing infrastructure. 5. Quality Power Quality Power is a high-voltage electrical equipment maker sitting at the intersection of India's grid modernization, energy transition and renewable integration. It sells the heavy-duty equipment that regulates current and stabilizes the grid when big loads (data centers) or variable sources (solar, wind) connect, handling loads up to 765 kV and 1,200 kV. It supplies niche components to global majors such as GE, Hitachi Energy and Siemens. Its footprint spans Sangli (core business), Cochin (S&S Transformers), Bhiwadi (Mehru), Turkey (Endoks), Pune (Sukrut), Chennai (Nebeskie) and Visakhapatnam (WSIL, post-acquisition). Revenue splits roughly into Power Products (60-65%), Power Quality Systems (30-35%) and backward-integrated components via Sukrut (5-8%). Key products: The portfolio spans air-core and iron-core reactors (which control current flow), specialised coils, line/wave traps, instrument transformers (the "eyes of the grid", via Mehru, up to 500 kV), cast-resin and special-purpose transformers (via S&S, up to 170 kV), and capacitor banks and harmonic filters for reactive-power compensation and cleaner power. On the active side, Endoks makes SVCs and STATCOMs (~25% margin per management) and is developing BESS power conversion systems (~18% margin). Reactors and coils serve harmonic filtering, current limiting, FACTS and HVDC applications. The company is not a single-product story: it spans equipment that carries, measures, protects, stabilises and controls power across the HV grid stack. Future growth drivers: The core driver is the ~8x capacity expansion at the new Sangli plant, lifting peak revenue potential from ~₹250 Cr to ₹1,500-2,000 Cr, with commissioning due by mid-2026 followed by customer audits. Beyond that are several optionalities tied to the global grid capex cycle: BESS (management targets $60-$80 mn of orders by end-FY27, with ₹350-390 Cr expected over 12 months), HVDC (reactors and ~₹500 Cr of added insulator opportunity), GIS instrument transformers via the Hyosung T&D co-development (monetisation from FY28), and insulators via the WSIL acquisition (₹315 Cr EV, targeting ~₹200 Cr revenue by FY28, plus 36 acres of SEZ land and in-house supply security). The order book of ₹1,950 Cr (up 151% YoY) gives ~15 months of visibility, and management guides to 20% growth in FY27 (possible Q3 revision) and 50% in FY28, with high-teens to ~20% EBITDA margins. While the TTM valuatrion looks expensive, they are expected to post more than 300cr PAT in FY28! That's all for this edition. Have a great Sunday! Disclaimer: None or buy or sell recommendations. This publicly available information is shared for learning and education purposes.
17
40
1
371
37,504
Budding_Trader retweeted
Attended HIE event Sep'26 in Hyderabad and had a nice interaction with knowledable and intelligent investing community Thanks @LearningEleven Discussions revolved around with obvious names Neuland, Laurus, Divis,Sai lifesciences, Qpower, Avantel, Qline biotech, Raghav productivity and few more names like YashHv, E2E networks, Monolithisch, Menon and NRB bearings, SBCL, Ather, Dee development, RKForge, Macpower and jyoti cnc, Shree ref, Shilpa Medicare, Digilogic, Steelcast, Emudhra, Symbiotic, Sal steel, Lords Marks industries, Aarti pharmalabs, SBCL, Concord biotech, Meesho Do due diligence and dont buy blindly
6
21
136
9,311
Budding_Trader retweeted
For the past 4 years, several respected and well-meaning voices have repeatedly warned investors about small caps, midcaps and SMEs. Alongside this, we have consistently heard that large caps are relatively cheaper and that money should rotate towards them. The concerns have not been entirely misplaced. There has been speculation, weak governance and unjustifiable valuations in parts of the market. But identifying excess in some companies is very different from declaring an entire segment unattractive or repeatedly calling a market top. A valuation call by itself is rarely enough for me to take meaningful money out of equities as an asset class. I would consider doing that when excessive valuations along with investor leverage and excessive corporate leverage come together with a business cycle that is on the verge of turning. That is when the risk becomes systemic. Companies can go bust, capital structures can unravel and businesses that never deserved their valuations can fall 90–99%. That is not an ordinary market correction. It is permanent destruction of capital from which many companies never recover. Current market conditions do not remotely resemble that setup. We do not see excessive leverage across investors and corporates, nor does the business cycle appear to be on the verge of a major downturn. Corporate balance sheets are broadly healthy and several investment cycles are still unfolding. This is why repeated valuation-led calls on the market have largely been ignored. The market may correct, consolidate or rotate. Individual stocks can certainly fall sharply. But without systemic leverage and a turning business cycle, a broad call to move away from equities can create more opportunity loss than protection. Many investors would have been better served by spending less time debating small caps versus large caps and more time identifying where the next profit pools were emerging. The opportunity was never in a market-cap category. It was in businesses undergoing meaningful change. This is also why we prefer to begin with themes rather than valuation screens. Where is the world changing? Which industries are reaching an inflection point? Where are new profit pools being created? Which companies have the capability and the right to win? Valuation comes after understanding the opportunity. If the starting point is purely mathematical valuation, many of the biggest opportunities will appear expensive precisely when their future is beginning to change. A screen can tell us that 10x P/E is cheaper than 40x. It cannot tell us when 10x is expensive and 40x is cheap. The job is not to permanently favour small caps, midcaps or large caps. Nor is it to keep predicting the next market top. The job is to keep finding new themes, identify the businesses best placed to capture them, pay a sensible price and remain invested while the thesis plays out. Risk must be respected. But opportunity cost is also a risk. #markets #thematicinvesting #marketcapagnostic
13
49
7
295
45,007
RT @alphaaffairsf2f: Observation Bull market and so called concentrated approach First things first Concentration produces wealth Diversi…
1
1
Markets, Biases and Survival ~~~~~~~~~~~~~~~~~~~~~~~~~~ Markets have a funny way of teaching you the same lesson over and over again. Human beings are biased. We always have been. We always will be. The trick isn't to become unbiased. It's to recognize your biases, listen when someone sees what you don't, and manage risk while the story is still unfolding. Because markets today can do something extraordinary. A company can go up 100x and then fall 90%. Then comes the circus. Was it a fraud? Who knew? Who warned everyone? Who called it first? Everyone has a story. Everyone has a verdict. But none of that puts money in your account. The finfluencer's job is to say, "I told you so." Your job is different. Make money. Enter reasonably well. Exit reasonably well. Allocate reasonably well. And above all, don't get wiped out. There will always be noise. Narratives. Opinions. Biases. People explaining yesterday and predicting tomorrow. You don't have to process all of it. Watch the trend. Ride it while it's intact. When it starts to fade, step aside. You don't need to predict the top. You don't need to explain every move. You don't need to win every argument. You need to survive. Eliminate the risk of ruin. Keep playing. Keep repeating. Keep learning. And with every cycle, understand one thing a little better: Yourself. Because investing isn't just about finding the right company or having the right opinion. It's about managing your own biases well enough to stay in the game. Long enough to compound.
3
9
3
37
6,600
Budding_Trader retweeted
🎬 THE COMPANY THAT BUILT A RUNWAY AND IS NOW ASKING THE WORLD TO WATCH IT FLY There is a moment in every great growth story where the company stops describing what it hopes to become and starts describing exactly how it plans to get there. AXISCADES just reached that moment. And the way they described it should give you goosebumps. "Built the Runway. Ready for Take-off." That is not marketing copy. That is the actual title the company chose for its own Annual Report. And once you understand everything that sits behind those five words, you will understand why this might be one of the most exciting inflection points in Indian aerospace and defence right now. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 📖 CHAPTER ONE: THE FOUNDER WHO CAME BACK TO FINISH WHAT HE STARTED Every great comeback story needs someone who refuses to let the ambition die quietly. Dr. Sampath Ravinarayanan built AXISCADES in 2007 into a company trusted by Airbus, Thales, MBDA and Boeing. Then he stepped back. The company drifted through a quiet decade. Nothing broke, but nothing roared either. Then he came back. Not as an advisor watching from the sidelines. As Founder, Chairman, and Managing Director, holding the wheel with both hands. And in his own words to shareholders, here is exactly what he is building toward. "Power 930 is not a number we hope to reach. It is the discipline by which we choose what to build, where to invest and what to decline. Scale without discipline is not value creation. Our aim is purposeful scale, supported by resilient economics." Read that again. This is not a founder throwing out a big number to excite the market. This is a founder describing an operating philosophy, where every rupee has to earn its place before it gets spent. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🚀 CHAPTER TWO: THE VISION BEHIND THE NUMBER Before you get to the money, you have to understand what this company actually believes about its own future. Straight from the Annual Report, here is the mission they have written down for themselves. "To be a product-driven, non-linear technology leader in Aerospace, Defence and ESAI, delivering cutting-edge innovation and creating enduring value for stakeholders." Notice the phrase non-linear. That is the whole game. A services company grows the way a person grows old, one year at a time, one hire at a time, revenue tracking headcount almost exactly. A product company grows the way a wildfire spreads. Slowly at first, then suddenly everywhere at once. AXISCADES is deliberately trying to stop being the first kind of company and become the second. And here is the proof it is already starting to work. Revenue per employee climbed to ₹39.94 lakh in FY26, up from ₹35.65 lakh the year before. That sounds like a small number until you realise what it actually means. The company is finding a way to earn more from the same person, the same desk, the same factory floor. That is the earliest signature of non-linear growth, showing up quietly in the numbers before anyone was watching for it. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🩸 CHAPTER THREE: THE PRICE OF BUILDING SOMETHING BIGGER No runway gets built for free. In May 2026, AXISCADES sold its Heavy Engineering, Energy and Automotive business for ₹292 crore. Seventeen days later, in June 2026, it sold something far bigger, its entire Aerospace Engineering Services business, the very thing that built its name, for ₹1,964 crore. Together, ₹2,256 crore. And ₹1,685 crore of that is not a forecast. It is a guaranteed minimum, locked into signed contracts. The CFO, Shashidhar SK, described exactly what this money is for, and the phrase he used should be the one you remember. "This capital provides the Group with the institutional-grade stability to fully fund the organic and inorganic milestones of the FY2030 vision without reliance on high-cost borrowings." No dilution. No desperate fundraise. Just an old identity sold at a price high enough to build a much bigger one. And here is the part that should genuinely excite you. This is not an exit. AXISCADES keeps a 49% stake in the divested aerospace business for up to thirty months, meaning the relationships, the reputation, and the institutional trust built over sixteen years does not vanish overnight. It compounds forward, quietly, in the background, while the company builds its next chapter in the foreground. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 😰 CHAPTER FOUR: THE QUARTER THAT LOOKED SCARY BUT WAS ACTUALLY THE PLAN WORKING Here is where most investors would have panicked, and where the story actually gets exciting if you know what to look for. Q1 FY27, the quarter ended June 30, 2026, reported a loss of ₹14.8 crore. A year earlier, the same quarter had delivered a profit of ₹20.9 crore. But the CFO had already told you this exact moment was coming. "For now, we are paying for the company we are building while still running the business we divested. Expensive for one quarter, compounding for the next forty." Strip out ₹21.81 crore of one time divestment costs and a ₹9.62 crore provision on one old receivable, and normalised profit was actually positive ₹20.2 crore, almost flat year on year. And underneath that headline, the real engine was roaring. The retained business, everything left standing after the sale, grew revenue 94.2% year on year. From ₹94 crore to ₹183 crore, in one single quarter. That is not a company falling apart. That is a company mid sprint, breathing hard, exactly where it planned to be. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🔥 CHAPTER FIVE: FOUR ENGINES, ALL FIRING AT ONCE 🛡️ Defence just posted something the Annual Report itself called out with visible pride. Segment revenue grew 24.7% for the full year to ₹377.70 crore, but segment profit grew an extraordinary 91% year on year. Growth alone is common. Growth where profit grows four times faster than revenue is the signature of a business finally earning what it is worth. And the growth is only accelerating from there. In Q1 FY27, Defence revenue jumped 111% year on year to ₹125 crore, and the Chairman promised this is just the beginning. "On this foundation, we expect Defence to deliver 75% year-on-year growth in FY27 and years ahead." Behind that promise sits ₹4,557 crore of Assured Forecast Visibility as of August 2026, up from ₹4,350 crore three months earlier, even after ₹125 crore of it had already converted into real revenue. New wins are arriving faster than old ones are being cashed in. 🤖 XiDA, the AI and semiconductor platform, is the fastest engine of all. It grew 62% year on year to ₹49.5 crore at a 29.7% margin in a single quarter, and in that same quarter landed two of the largest technology companies on the planet as customers. "Three of the world's top five technology and hyperscale companies, and the largest semiconductor equipment manufacturer, are now our customers. We are confident of more than 100% year-on-year growth in XiDA starting FY27." ✈️ Aerospace is still early, still investing ahead of revenue, but the company has already done the math out loud. ₹74 crore of divested Aerospace EBITDA needs replacing. A first acquisition already brings back ₹39 crore of it, annualised, with a target of crossing ₹375 crore in annualised revenue by Q4 FY27. "Supported by the fully funded Power 930 roadmap, the Aerospace business is architected to be a primary driver of the Groups trajectory toward FY2030." 🚀 Space is the spark that could become the biggest surprise of all. A satellite manufacturing and integration facility is already under construction at DAC. Full partnership details arrive at the Bengaluru Space Expo and World Space Business Week in Paris, both in September 2026. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🏭 CHAPTER SIX: ONE FACTORY DESIGNED TO SERVE FOUR FUTURES AT ONCE Here is the single most beautiful piece of engineering logic hiding inside this entire story, and it has nothing to do with software or slide decks. It is physical. The same composite manufacturing lines. The same precision machining equipment. The same testing infrastructure. One shared factory base at Devanahalli, twenty acres, roughly 3.12 million square feet of planned built up area, feeding aerospace parts, missile components, and eventually satellite structures, all from tooling that only had to be paid for once. The COO described exactly why this matters in his own words. "These tri-use facilities utilise common technologies that serve Aerospace, Defence, and Space simultaneously, generating structural operating leverage and shortening programme mobilisation timelines." Translate that sentence into something you can picture. Every time this company wins a new contract in any one of its four platforms, the cost of saying yes gets cheaper, because the equipment answering that yes was already built for someone else's order. That is how a company grows margins while it grows revenue. Not by cutting costs. By making every rupee of infrastructure work four jobs instead of one. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🔮 CHAPTER SEVEN: THE FUTURE THIS IS ALL BUILDING TOWARD Now here is the part worth genuinely getting excited about. Not the next quarter. The next four years. The target on the wall is ₹9,000 crore of revenue and ₹960 crore of profit by FY2030. From a base of roughly ₹1,159 crore today. That is not incremental growth. That is the company betting its entire structure on becoming eight times bigger inside four years. And the roadmap for getting there is not vague. It is tranche by tranche, platform by platform, dated on a calendar. 💰 ₹906 crore of already guaranteed cash lands in Q3 FY27 💰 ₹126 crore follows in H1 FY28 💰 The final ₹1,224 crore closes out in FY29, right as the last mile to FY2030 begins That capital gets deployed with surgical precision. ₹600 crore into Defence Solutions to build OEM-certified manufacturing capacity around twenty one active design wins. ₹600 crore into Aerospace Manufacturing, split between acquisitions and factory scale up. ₹300 crore into XiDA to acquire AI-native engineering capability and lock in Tier-1 technology customer access. ₹300 crore into Space, funding satellite bus manufacturing and joint ventures. And ₹300 crore into the shared infrastructure that makes every other platform cheaper to run. Here is how the Annual Report itself describes what this unlocks. "Ensuring the transition from a gradual ascent to a step-function in revenue and PAT." A gradual ascent is what most companies promise. A step function is what almost none of them deliver. AXISCADES just told its own shareholders, in writing, that gradual is no longer the plan. And the Aerospace platform alone is targeting ₹1,000 crore by FY2029, up from a near standing start today. Defence is compounding at 75% a year against a pipeline that keeps refilling itself faster than it empties. XiDA is doubling. Space has not even opened its first chapter yet. Stack all four of those trajectories on top of each other, funded by cash that is already contractually locked in, running through factories designed to get cheaper with every new order, and FY2030 stops sounding like a slogan. It starts sounding like arithmetic. ━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━ 🎯 CHAPTER EIGHT: WHY THIS IS THE MOMENT TO BE PAYING ATTENTION The runway is built. The cash is contracted. The factories are rising out of the ground in Devanahalli and Hyderabad right now, this quarter, not someday. Four engines are already running, at different stages of ignition, but every single one of them is pointed in the same direction. The Chairman closed his own letter to shareholders with a line that deserves to be the final word here too. "Having built a robust runway in Fiscal 2026, AXISCADES is now cleared for takeoff toward our Power 930 vision." A runway only matters the moment something actually leaves the ground. And for the first time in this company's history, every piece required for that lift-off, the cash, the factories, the customers, the design wins, is sitting on the tarmac at the same time. The next four years will decide whether this becomes the story every Indian aerospace and defence investor wishes they had caught earlier, or a lesson in how hard it is to turn eight times ambition into eight times reality. Either way, for the first time in years, this is a company that is not asking you to imagine its future. It is showing you the exact dates it plans to arrive. #Axiscades @AXISCADES
7
8
33
3,618
I attended a big investing forum last year Observations: Random discussion on many stocks Most of the guys just want to validate their thesis --and not hearing out what others have in store for the same stock ---Basically only want to hear that they have chosen a good stock In that moment itself, I was thinking why I am here!! Its a waste of time Only thing that could have been useful is networking opportunities---but believe me -- everyone will finish their buying first and not tell you anything before the stock rises 3x-5x and then come back to you --look at that --thats doing well --we are invested why they are telling now ---to just validate their thesis Price is running up--so everyone says --wow Nobody tells the risk in it and obviously you dont want to hear out as well And life goes on.... I am penning this thought --because I brought up a stock to notice of some so called great investing minds and they ignored/overlooked it And today that stock in one year has been sitting on 10X Yia its just 10x It was the starting point of ALD1.0 after coming back and created something which is very very useful for investors We discussed 12 stocks in ALD1.0 and ALD2.0 in terms of business, risks, opportunity size 3-4 stocks have become 3x-4x from that point and many have becomes doubled (ofcourse bullmkt played a role, but getting 4x in less than 10 months is luck + right process) ALD3.0 (july24) --discussing 18 potential companies in terms of business, opportunity, triggers, turaround Only serious investors, traders join ALD (ALPHA LEARNERS DAY) --I am proud of the group who keep digging opportunities and churn out multibaggers #StocksInFocus #BREAKOUTSTOCKS #StockMarketindia #StocksToBuy #StocksToWatch #StocksToTrade #stocksinnews #StockMarket #StockMarketindia #stockmarkets #nifty50 #Nifty #NiftyBank #nseindia #stockmarketcrash Marine electricals which is flying now is discussed in detail in ALD1.0 Raymond special situation is discussed in ALD2.0 HBL power discussed in ALD1.0 So whats special discussed in ALD3.0!!! Watch out for this space --you will have free videos of all sessions
7
11
1
49
4,827
Budding_Trader retweeted
Timepass talk on Sunday 1. Nephrocare Health Services Think of your kidneys as your body's personal waste-treatment plant. Every single day, they filter roughly 150–180 liters of fluid from your blood, removing waste, excess water, and helping maintain the right balance of salts and minerals. When your kidneys lose around 85–90% of their function, they can no longer adequately perform these vital jobs. Waste products and excess fluid can begin building up in the bloodstream, potentially becoming dangerous. Dialysis is a treatment that takes over part of the kidneys' filtering job when they can no longer do enough of it themselves. It removes waste and excess fluid from the blood, but it does not replace everything healthy kidneys do. NephroPlus is India’s and Asia’s largest dialysis network and the world’s fifth largest, operating over 550 clinics across five countries, India, the Philippines, Uzbekistan, Saudi Arabia, and Nepal, serving more than 38,000 guests. The company operates as a pure-play, end-to-end dialysis platform delivering care through multiple formats including in-hospital captive centers, public-private partnerships (PPPs), standalone clinics, home hemodialysis, and mobile services. It leverages an asset-light, scalable operating model built on centralized global procurement, in-house biomedical engineering, proprietary technology such as the Renova dialyzer reprocessing system, and protocol-driven clinical quality, while partnering with government health schemes and insurers to maintain affordability and access. NephroPlus’s growth is underpinned by three key levers: consolidating leadership in India as the market shifts from unorganized to organized care (currently only ~21% organized), scaling its international footprint in higher-price markets where realizations are 3–13x above India, and pursuing disciplined acquisitions and PPPs to expand capacity. They plan to add 40-50 clinics in India and 10-15 in the Philippines annually. The business benefits from powerful macro tailwinds including rising diabetes and hypertension driving chronic kidney disease, significant under-penetration relative to global benchmarks, and strong operating leverage that has expanded adjusted EBITDA margins to 23.1%. Complementing this are strategic initiatives such as the NephroPlus International Dialysis Academy (NIDA) for renal nurse training, AI-driven clinical and operational tools, and a roadmap to enter a new international market every 12–18 months, all supporting scalable, capital-efficient expansion. 2. Tunnel Boring Machine (TBM) When you think of massive infrastructure programs such as Urban Metro Networks, High-Speed Rail & Expressways, Undersea Rail Tunnels, Hydroelectric Power & Strategic Tunnels, and Water & Sewage Infrastructure, there is one common element that quietly powers many of these projects: the Tunnel Boring Machine (TBM). A Tunnel Boring Machine (TBM), often called a "mole", is a massive, cylindrical piece of heavy equipment used to excavate circular tunnels through earth and hard rock. Instead of traditional drilling and blasting, a TBM uses a rotating front "cutterhead" equipped with heavy disc cutters to slice through rock or soil, automatically lining the tunnel with pre-cast concrete segments as it advances. For decades, India has been heavily dependent on overseas suppliers for TBMs, with most machines and critical components sourced from countries such as China, Germany, Japan and Australia. Domestic manufacturing capability has historically been limited, making TBMs a largely import-dependent segment. The Indian central government finalized a $1.2 billion PLI-style incentive scheme targeted at boosting domestic manufacturing of high-value construction and mining machinery. This initiative focuses directly on creating local capacity for high-end equipment like TBMs to curb dependence on imports. Herrenknecht India (subsidiary of Germany-based Herrenknecht AG) established a dedicated plant near Chennai where up to 60–70% of non-critical structural components are localized, assembling machines domestically while importing only the specialized European core components. Indian engineering firms like BEML are collaborating with international partners to build capabilities to design and manufacture indigenous TBMs. A TBM is a highly engineered machine containing substantial amounts of castings, forgings, machined components, shafts, gears, housings, cutter assemblies, structural components, etc. As localisation increases, OEMs will look to localise more of these components to reduce cost, lead times and import dependence. 3. Casting, Forging and Machining The US heavy-duty truck market (Class 8) in 2026 has seen an intense, record-breaking front-half of the year, driven heavily by the "pre-buy" race to secure current-generation diesel slots before the strict 2027 EPA guidelines hit production. Caterpillar is operating at or near effective capacity in its power generation business, with a $72 billion backlog (nearly 3.5x what it was 18 months ago) and delivery slots extending to 2029–2030. The company is responding with an unprecedented capacity buildout (tripling large engine capacity, 2.5x-ing turbines), but the gap between demand and supply won't close quickly. When you combine the Class 8 truck backlog stretching into 2028–2029, Caterpillar's record $72 billion order book with deliveries into 2030, aerospace's 16,683-aircraft backlog representing 12 years of production, India's defence capital outlay of ₹2.19 lakh crore with a 75% domestic procurement mandate, Wabtec's $27 billion rail backlog, and the global offshore wind pipeline of ~500 GW, all of which are metal-intensive, long-cycle industries hitting capacity constraints simultaneously, the casting, forging and machining space appears to be in the early innings of a genuine multi-year cycle. Which forging or casting company one chooses to pick is a personal choice, but the underlying story certainly seems to be coming together. 4. Peptides It took decades for around 110-130 peptide drugs to reach FDA approval. Today, nearly 800 peptide drugs are already in development, a striking indication of how rapidly the peptide therapeutics pipeline is expanding. A peptide is a short chain of two to fifty amino acids linked by chemical bonds. Because amino acids are the building blocks of proteins, peptides are essentially mini-proteins. They act as tiny messengers in the body that tell cells what to do. Human body uses native peptides constantly as messenger molecules to control naturally occurring processes: Insulin (51 amino acids) tells your cells to absorb sugar. Oxytocin (9 amino acids) manages social bonding and contractions. GLP-1 (30 amino acids) tells your brain you are full after eating. When scientists develop a peptide drug, they aren't inventing a completely foreign, synthetic chemical that the body has to figure out. They are copying or lightly tweaking a "native text" your cells already know how to read. Peptides have existed for decades, but only recently have they emerged as a major growth area in therapeutics as several long-standing development and manufacturing constraints have been successfully addressed. Historically, peptide drugs were challenging and costly to manufacture at commercial scale, often characterized by low yields, impurity-related issues, and complex production processes. However, advancements in solid-phase peptide synthesis (SPPS), automation, purification technologies, and process engineering have substantially improved manufacturing efficiency, product quality, and scalability, making large-scale commercialisation increasingly feasible. Peptide drug development has gained significant momentum in recent years, driven by the commercial success of GLP-1/GIP therapies and advances in manufacturing technologies that have improved scalability, yields, and cost efficiency. The peptide pipeline is now deeper than ever, with ~800 peptide molecules under development globally, including ~600 in preclinical stages and ~185 in clinical development. Notably, nearly 100 peptide candidates are already in Phase 3 trials, highlighting the strong probability of future commercial launches. We believe this expanding pipeline, coupled with growing interest in metabolic, cardiovascular, oncology, and rare disease indications, will continue to drive robust demand for peptide manufacturing capacity over the coming decade. Bottom line, Indian CDMO companies with Peptide capacities are expected to be in the middle of a super-cycle! Now, go look for those! 5. Motilal Oswal Financial Services Motilal Oswal Financial Services (MOFSL) is India’s largest integrated non-bank capital market player, operating across Asset Management, Private Wealth, Retail Wealth Management, Capital Markets (Institutional Equities & Investment Banking), Housing Finance, and a strategic Treasury Investment book. The company has delivered a decadal Operating PAT CAGR of 33% and an average ROE of 23% entirely through internal accruals, with zero equity dilution since its 2007 IPO. MOFSL is successfully transforming from a cyclical brokerage-heavy firm into a steady-state Asset and Wealth Management (AWM) machine. Q1FY27 marks an inflection point: Asset Management + Private Wealth now contribute 55% of group Operating PAT (vs. 42% in FY25), driving the ARR (Annual Recurring Revenue) mix to a record 66%. With a treasury book compounding at 41% CAGR, and multiple structural tailwinds (financialization of savings, rising HNI/UHNI wealth, India’s capital market deepening), MOFSL is transitioning from a cyclical broking-led franchise to a high-quality, annuity-heavy compounder. The shift from Transaction-Based Revenue (TBR) to ARR looks structural. Fee & NII revenue share now stands at 78% of total revenue, significantly de-risking the P&L from market volatility. AMC business: Asset Management (Mutual Funds + PMS + AIF) is the new growth engine (73% PAT Growth) and is firing on all cylinders Private Wealth Management: PWM business caters to 400+ UHNI families with an AUM of ₹2.4 lakh Cr (Grew 42% YoY in Q1) Alternates Expansion: Management plans to launch a commercial real estate fund in H2 FY27 and is finalizing its maiden private credit fund of ₹3,000 crores. Capital Markets: Ranked #2 in IPO/QIP league tables for Q1FY27The "Twin-Engine" Model Creates a Self-Sustaining Compounding Machine Housing Finance: PAT up 36% YoY to ₹32 Cr. AUM at ₹6,164 Cr (up 23% YoY). Pristine asset quality (GNPA 1.1%, NNPA 0.6%). Disbursements grew 64% YoY. That's all for this edition. Have a great Sunday! Disclaimer: None or buy or sell recommendations. This publicly available information is shared for learning and education purposes.
24
43
2
435
48,715
Budding_Trader retweeted
🔥 Key Takeaways From Ishmohit Arora’s Pune Session on New Age Manufacturing 🔥 Pune Event Takeaway I recently watched Ishmohit Arora’s Pune session on New Age Manufacturing. What stood out was not a stock idea. It was the way the entire manufacturing ecosystem was connected from raw materials and processes to precision engineering, electronics, aerospace, defence, robotics and advanced manufacturing. Here are my key takeaways from the session. 1. 🔥 India’s Manufacturing Opportunity The world is rethinking supply chains. Cost is no longer the only factor. Geopolitics, tariffs, supply chain security and the China plus one strategy are pushing global companies to diversify manufacturing. This creates a major opportunity for India. 2. 🔥 Assembly Is Only the Beginning India has built strong assembly capabilities in many industries. But the bigger opportunity is moving deeper into the value chain. Raw materials to processes to components to precision components to sub assemblies to systems and eventually design led manufacturing. The higher India moves in this chain, the more value it can capture. 3. 🔥 Processes Are the Foundation Forging, casting, machining, sheet metal, fasteners and other manufacturing processes may look basic. But these processes are the foundation of automotive, aerospace, defence, industrial equipment and many other industries. The real advantage comes from consistently producing complex parts with high quality and tight tolerances. 4. 🔥 Precision Engineering Precision manufacturing is not simply about buying an expensive machine. It requires tooling, process knowledge, quality systems, skilled people, inspection and years of learning. This accumulated manufacturing knowledge can become a strong competitive advantage. 5. 🔥 The Machine Layer One of the interesting points from the Pune session was the importance of CNC machines and machine tools. India is becoming a bigger producer of precision components, but it still imports a large part of the machines required to manufacture those components. This shows that the opportunity exists both in making the components and in building the machines that make those components. 6. 🔥 Automation Does Not Remove the Human Moat A CNC machine can repeat the same operation with extraordinary accuracy. But manufacturing still needs people who understand tooling, fixturing, process changes, quality problems and real world production conditions. This becomes even more important in aerospace and defence where production volumes can be smaller and specifications can be much more demanding. 7. 🔥 Aerospace Is a Capability Game Aerospace manufacturing requires much more than producing a component. Suppliers need precision, qualification, traceability, consistency and strict quality systems. Once a supplier develops these capabilities and gets qualified, the relationship can become much harder to replace. India is already becoming an important part of global aerospace supply chains. 8. 🔥 Defence Manufacturing Is Moving Deeper India’s defence manufacturing ecosystem is expanding. The important change is not only higher domestic production. It is the development of a deeper supplier ecosystem involving components, systems, precision engineering and specialised manufacturing capabilities. This can create capabilities that are useful across aerospace, defence and other advanced industries. 9. 🔥 Electronics Is Moving From Assembly To Integration India has already built large electronics assembly capabilities. The next step is much more important. Can India manufacture more of the components that go inside those products? PCBs, displays, electromechanical parts, power systems, semiconductor packaging and other components can help India capture more value from the electronics supply chain. 10. 🔥 PCB Backward Integration The shift is visible across the electronics ecosystem. Assembly can be followed by PCB fabrication, HDI and advanced PCB technologies, component integration and semiconductor packaging. This is the difference between simply assembling a product and building a deeper electronics manufacturing ecosystem. 11. 🔥 The Bill of Materials Matters The biggest opportunity may not always be the final product. It can be hidden inside the product. Every phone, vehicle, aircraft, machine and electronic system contains hundreds or thousands of components. Capturing more of that Bill of Materials can gradually increase the value India captures from manufacturing. 12. 🔥 Physical AI Is a Manufacturing Opportunity Humanoid robots make this even more interesting. A humanoid requires actuators, reducers, sensors, motors, bearings, batteries, power electronics and computing. This means the robotics opportunity is not only about the final robot. It can create an entirely new ecosystem of precision component manufacturing. 13. 🔥 Advanced Manufacturing Needs Advanced Materials New manufacturing industries also require better materials. High performance alloys, speciality metals, engineered materials and specialised chemicals become increasingly important as applications become more demanding. This creates opportunities further upstream in the manufacturing chain. 14. 🔥 Specialty Chemicals The value in specialty chemicals is often not simply the volume produced. It comes from formulation, process knowledge, purity, consistency, customer qualification and application expertise. That creates a very different type of manufacturing business from commodity production. 15. 🔥 Pharma Is Also Moving Up the Value Chain The interesting areas discussed in the session included CDMO, peptides, biosimilars, injectables, sterile manufacturing and specialty chemicals. These areas require strong manufacturing processes, regulatory capabilities and customer trust. Again, the theme is the same. Move from basic capacity towards specialised capability. 16. 🔥 The Value Added Curve One of the strongest ideas from the session was how manufacturers move up the value added curve. First comes a product with better realisation. Then products that are harder to manufacture. Then increasingly difficult manufacturing processes. Finally, capabilities that competitors cannot easily build themselves. Each step requires capital, time and learning. 17. 🔥 Capability Creates the Moat A strong manufacturing moat can come from many things. A difficult process. A qualified product. A specialised workforce. A long customer approval cycle. A difficult manufacturing technology. Or years of accumulated production knowledge. These are much harder to replicate than simply adding factory capacity. 18. 🔥 Backward Integration Backward integration is becoming one of the biggest themes across Indian manufacturing. Companies are moving into components and processes that were previously sourced externally. The objective is not only cost reduction. It is greater control over quality, supply, technology and eventually a larger share of the value created. 19. 🔥 Scale Versus Localization The session also showed an important strategic difference. Some manufacturers focus on achieving massive scale through assembly. Others focus on localisation and deeper manufacturing capability. The strongest businesses may eventually combine both. Scale provides operating leverage. Localization provides control. Capability provides the moat. 20. 🔥 India’s Manufacturing Map Is Much Bigger Than It Looks The opportunity is not one single sector. It is a connected ecosystem. Materials Processes Machine tools Precision engineering Electronics PCB and PCBA Aerospace Defence Automotive Specialty chemicals Pharma Robotics Physical AI Advanced industrial manufacturing 21. 🔥 The Biggest Takeaway From The Pune Event The most important lesson I took from Ishmohit Arora’s session is that India’s manufacturing story should not be viewed sector by sector. It should be viewed as a value chain. The real question is not simply how much India can manufacture. The bigger question is how much of the value chain India can own. 22. 🔥 From Make In India To Make More Of The Value The next phase of Indian manufacturing could be about moving from assembly towards deeper capability. More components. More processes. More engineering. More localisation. More design. More specialised manufacturing. More control over the supply chain. That is where the real value creation can happen. 23. 🔥 Final Takeaway The Pune session made one thing very clear. India does not need to win every manufacturing category. It needs to become exceptionally good at the parts of the value chain that are difficult to replicate. That is where manufacturing capability becomes a moat. And that is what makes India’s New Age Manufacturing story so interesting.
20
74
2
427
37,996
Budding_Trader retweeted
Timepass talk on Sunday 1. Marksans Pharma Marksans Pharma is a globally focused consumer healthcare and generic pharma company with a dominant presence in OTC (over-the-counter) store brands. It manufactures and markets 350+ products across 2,000+ SKUs, primarily for regulated markets including the US, UK, Europe, Australia, and Canada. The company operates 4 manufacturing facilities (India, US, UK) with 26 billion units of annual capacity and is amongst the top 5 Indian pharma companies in the UK by revenue. Top Growth Drivers The company's growth is being propelled by four key engines. First, European front-end expansion is the most significant new driver, Marksans has acquired QliniQ in the Netherlands (contributing ₹44 crore in Q1FY27) and ABCnow in Germany (consolidating from Q2), while also establishing new entities in Ireland and Germany, with Europe revenue already surging 75% YoY. Second, product pipeline momentum remains robust with plans to launch 20–25 new products annually, 112 SKUs added in the US in FY26, and a target to double the portfolio in every country over the next 2–3 years. Third, manufacturing scale and operating leverage is improving as Goa Unit 2 (acquired from Teva) ramps toward ₹80 crore revenue, and the company aims to expand total Indian capacity from ~8 billion to 16 billion units per annum. Fourth, new geography entry through Canada (entity incorporated, filings underway) and continued strength in Australia/New Zealand (54% YoY growth in Q1 with new Rx brand launches under Nova Pharma) is diversifying revenue beyond the traditional US and UK markets. How Big Could the Europe Opportunity Be? Europe is rapidly emerging as Marksans' most exciting new growth frontier. In FY27, management expects the region to generate approximately ₹180 crore in revenue, a sharp step-up from the sub-€10 million historical run-rate at QliniQ, reflecting both the acquired base and roughly 40% organic growth expected. Looking further out, management has explicitly guided that they hope Europe can reach "about thousand odd crore" (~₹1,000 crore) within 3–5 years, driven by additional acquisitions and scaling the existing platform across more European countries. The strategic appeal is heightened by Europe's prescription-heavy market structure (80–90% Rx versus 50–50 in the UK), which offers higher-margin, stickier revenue streams compared to the company's traditional OTC-heavy portfolio. Bottom line: Marksans offers a rare combination of high-teens revenue growth, expanding margins, net-cash balance sheet, and a clear M&A-driven geographic expansion roadmap, all at a scale where the company is transitioning from a niche OTC player to a multi-continent consumer healthcare platform. Now, what's the anti-theis, that's for you to figure out! 2. Sona BLW Precision Forgings Sona Comstar is executing a bold "Sona Comstar 2.0" strategy that aims to replicate its historical 10x revenue growth over the next decade. The company delivered its best-ever quarter in Q1 FY27 with 54% revenue growth, 49% EBITDA growth, and 45% PAT growth. What makes this growth particularly impressive is its quality and diversification, BEV revenue surged 107% YoY to ₹435 crore, now constituting 44% of automotive product revenue, while the company simultaneously won significant hybrid and ICE programs. The management has demonstrated exceptional capital allocation discipline, having invested ~₹2,750 crores across acquisitions (Comstar, NOVELIC, Railway Business) that now contribute roughly 40% of revenue, alongside organic innovation where over 35% of revenue comes from products that didn't exist seven years ago. New Growth Verticals The recently announced DENSO joint venture represents arguably the most important strategic partnership in the company's history, filling a critical gap in high-voltage electric and hybrid powertrain systems for passenger and commercial vehicles. This two-JV structure, where DENSO leads the 4-wheeler high-voltage segment and Sona Comstar retains control of the 2/3-wheeler segment with reciprocal royalty arrangements, provides access to world-class technology while validating Sona's own IP. Equally significant is the company's early and substantive entry into Robotics and Physical AI, a market management believes could be transformational given AI's emergence as the next general-purpose technology. With three orders already secured (aggregating ₹6 billion, taking the vertical's total order book to ₹8 billion), and SOPs beginning as early as next quarter, this is no longer conceptual, it is a real business with customers. The company's net order book stands at a robust ₹240 billion (5.4x FY26 revenue), with 64% from automotive EV, providing multi-year revenue visibility. Strong Market Position Sona Comstar holds dominant market positions, 55-60% share in Indian PV differential gears, 80-90% in CVs, and 75-85% in tractors, while expanding globally with 7 of the world's top 10 PV OEMs and 3 of the top 10 EV OEMs as customers. The company maintains a negative net debt position (net debt/EBITDA of -1.06x), providing significant balance sheet flexibility for future investments. Despite near-term margin pressure from input cost inflation and product mix (traction motors carry lower margins), management expects progressive improvement from Q2 onwards as cost pass-throughs materialize. With 69 EV programs across 36 customers, a technology roadmap spanning mechanical to software capabilities under "EPIC Mobility," and a proven ability to both build and buy capabilities, Sona Comstar appears well-positioned to capture outsized value as mobility undergoes its most significant transformation in a century. 3. Finolex Cables Finolex Cables is one of India's largest manufacturers of electrical wires and cables, with a dominant 23.9% market share in the organised wires industry. The company manufactures a comprehensive portfolio spanning electrical cables, power cables, communication cables (including optic fiber), switchgear, lighting, fans, water heaters, and conduit fittings. It operates five manufacturing facilities across India and sells through an extensive distribution network of ~800 distributors, ~5,000 channel partners, and ~2,15,000 retailers pan-India. Top Growth Drivers The company's growth is being propelled by four key engines. First, optic fiber and communication cables is the standout performer, Q1FY27 revenue surged 62% YoY with margins near 30% (which will normalize from Q2 on), driven by a global fiber shortage, AI/data center demand, and export opportunities to the US and Europe. The company is aggressively expanding fiber draw capacity from 4 million to 8 million km by Q2FY27 and cabling capacity from 8 million to 10 million. Second, electrical cables diversification continues with strong volume growth in auto cables, solar cables, agricultural cables, and flexible wires (all high double-digit growth), while the company is actively bidding for utility-side power cable projects and planning greenfield expansion once utilisation crosses 70%. Third, backward integration via preform manufacturing, the company has commissioned India's second preform plant (100 metric tons, equivalent to 4 million km fiber), eliminating import dependency, saving 5% duty, and creating potential for external sales; Phase 2 expansion is under evaluation given the demand boom. Fourth, FMEG scaling and channel expansion, despite Q1 headwinds from LPG shortages and PVC supply issues, the company maintains its ₹500 crore FMEG revenue target by FY28, with new product launches in fans and water heaters expected within 6 months and retail reach targeted to expand from 2,15,000 to 2,50,000 outlets. How Big Could the Communication Cables Opportunity Be? The communication cables segment is positioned for a step-change in scale and profitability. In Q1FY27, the segment generated ₹176 crore revenue (vs. ₹109 crore YoY), with exports contributing ₹35–40 crore. At full 8 million km fiber draw capacity and assuming $11/km fiber prices, management indicated potential revenue of ~$88 million (~₹730 crore) if selling only fiber, with an additional 25–30% value-add from cabling, implying peak potential revenue of ₹900 crore+ annually from this segment alone. The demand drivers are structural and global: AI-driven data center buildouts (hyperscalers investing $5–6 billion+ in India), 5G rollout completion by telecom operators, BharatNet Phase 3, and India's per capita fiber consumption at just 25 million km/year vs. China's 400+ million km, suggesting significant runway. Management also noted that fiber prices have risen from $5–6/km to $12–13/km currently, with premium fibers selling at $25–50/km, and that the global shortage is likely to persist. The company is also evaluating doubling preform capacity and has the technical capability to manufacture cables with fiber counts up to 14,000+ for data center applications. The balance sheet is exceptionally strong, net worth of ₹5,099 crore, negligible debt (debt-to-equity near zero), and cash equivalents of ₹163 crore, providing capacity for the ₹300 crore annual capex plan without strain. 4. Kusumgar Limited Kusumgar is an India-headquartered specialty engineered textiles and aerospace & defence solutions company with deep expertise in polyamide and polyester filament technology, polyurethane chemistry, and advanced fabric engineering. Founded in 1970 and listed on NSE/BSE in July 2026, the company manufactures high-performance fabrics for critical applications including parachute canopies, tactical clothing, camouflage systems, and bulletproof jackets, serving both as a fabric supplier and as a forward-integrated solutions provider for military and aerospace end-users. It operates six vertically integrated manufacturing facilities across Gujarat and Uttar Pradesh with a workforce of ~2,000, and holds the distinction of being one of only two global suppliers of zero-porosity parachute fabrics and the only Indian manufacturer of Kevlar filament fabrics. The company's moat is exceptionally wide, four to five decades of accumulated technical know-how in engineered fabrics, extensive qualification and approval barriers that take years to clear, exclusive global partnerships providing access to proprietary IP, and co-development relationships that translate into long-term sticky recurring business. Top Growth Drivers The company's growth is being propelled by four key engines. First, aerospace and defence solutions expansion, Kusumgar has successfully forward-integrated from fabric supplier to complete systems provider (parachute systems, camouflage solutions, rapid deployment systems), driving a significant portion of the ~7-8x revenue growth seen over the last five to six years; ready parachute contracts were a major contributor to Q1FY27's 102% YoY revenue growth. Second, indigenization tailwinds in Indian defence, India is accelerating its shift toward indigenous defence manufacturing to reduce import dependency, and Kusumgar is deeply embedded as an incumbent supplier to the Indian military with decades of qualification barriers and approval cycles that make switching costs prohibitively high for customers. Third, outdoor and lifestyle fabrics scaling, the company is rapidly building partnerships with global outdoor and activewear brands entering or expanding in India, with product approvals progressing brand-by-brand and season-by-season; this segment offers more predictable, recurring demand compared to the lumpy defence business. Fourth, global defence spending and export growth, the company is a challenger in international markets with growing inroads into foreign militaries, and management explicitly views geopolitical tensions and heightened global defence budgets as a secular tailwind; exports already contribute ~10-15% of revenue and the company has put in place arrangements to mitigate tariff risks. How Big Could the Aerospace & Defence Opportunity Be? The aerospace and defence segment is positioned for sustained multi-year growth driven by structural indigenization and global rearmament. In Q1FY27, the company reported revenue of ₹247 crore (up 102% YoY) with EBITDA margins of 31%, though management cautions that Q4FY26 was an anomaly due to tariff-resolution-driven export shipments, and Q1FY27 is more representative of normalized quarterly run-rates. Over FY20-FY26, revenue grew at a ~35% CAGR while PAT grew at an even faster ~70%+ CAGR, reflecting the shift from lower-margin fabric supply to higher-margin integrated solutions. The addressable opportunity is substantial: India's defence budget continues to expand, with increasing emphasis on domestic procurement; Kusumgar's product portfolio spans parachutes, tactical clothing, sleeping bags, rucksacks, bulletproof jackets, camouflage nets, and stealth systems, all of which have both steady replenishment demand (consumables for standing armed forces) and surge demand during geopolitical escalations. Management also highlighted partnerships in stealth/camouflage and lightweight carbon-based materials with Russian and Japanese technology partners, which could open new premium product lines. While management deliberately avoids formal guidance due to tender unpredictability, they indicated FY25 and FY26 margin levels (~19-27% EBITDA) are reasonable benchmarks for FY27, with the business broadly on track for continued steady growth. 5. Solar Industries Solar Industries is executing a compelling strategic pivot from a pure-play explosives manufacturer into a diversified defence-industrial complex, and the Q1 FY2027 numbers validate this thesis with force. The company delivered its highest-ever quarterly revenue (₹3,668 crore, up 70% YoY), EBITDA (₹1,024 crore, up 82%), and PAT (₹666 crore, up 89%), demonstrating that the defence vertical is not merely additive but multiplicative to profitability. With an order book of ₹21,350 crore, of which defence constitutes roughly ₹18,000 crore, the revenue visibility extends well beyond the current fiscal year. Management has guided for ₹14,000 crore in annual revenue (up from ₹9,800 crore previously), and has explicitly flagged potential upward revisions after H1, suggesting conservatism in their base case. The ~28% EBITDA margin, which management characterizes as the "new normal," is being structurally supported by a higher mix of defence products, efficient supply chain management, and recent capacity expansions. The defence segment is the critical engine for re-rating. It grew 123% YoY in Q1 and is targeting ₹4,500 crore for the full year. The Pinaka rocket system remains the anchor order, with extended-range variants (up to 75km) in final negotiation stages expected by H2. Beyond Pinaka, the Bhairavastra anti-tank guided missile is completing advanced trials with formal orders anticipated next year, while the 155mm artillery ammunition facility is being commissioned with initial revenue recognition in FY2028. These are not one-off contracts but platform-level opportunities that create annuity-like revenue streams and deepen the company's moat as India's first private-sector player in integrated defence manufacturing. The management's commentary on "increasing engagement with customers across domestic and international markets" implies export potential, which would further expand the addressable market. The balance sheet provides strategic flexibility without compromising returns. With approximately $80 million in cash and equivalents, the company is actively evaluating greenfield projects, acquisitions, and startup investments to augment organic growth. The planned capex of ₹2,050 crore for FY2027 (₹450 crore already deployed in Q1) is directed at capacity expansion in high-growth geographies, Dhule in Western India, Dholpur in the North, and upcoming facilities in Odisha and South India, ensuring that volume growth is not constrained by infrastructure. International explosives growth of 65% YoY, led by South Africa and Australia, confirms that the global footprint in 90+ countries is more than a marketing claim; it is a scalable revenue base. Now, what valuation offers you comfort is your own judgement! That's all for this edition. Have a great Sunday! Disclaimer: None or buy or sell recommendations. This publicly available information is shared for learning and education purposes.
24
84
1
594
67,284
Budding_Trader retweeted
Timepass talk on Sunday 1. Ujjivan Small Finance Bank If you look at the top 10 highest-volume trading days on the NSE over the last 12 months, four of them occurred on four consecutive trading sessions, July 23, July 24, July 27, and July 28. This highlights the exceptionally strong investor participation and heightened market activity following the earnings season. Why such interest? Strong Balance Sheet & Deposit Expansion: Ujjivan delivered a well-rounded quarter, with its gross loan book growing 28.9% YoY and deposits rising 25% YoY, supported by an impressive 37.8% YoY growth in CASA deposits. While many financial institutions have managed strong loan growth but struggled to mobilize deposits, Ujjivan successfully delivered healthy growth on both fronts, reflecting the strength of its franchise. Cost of Funds Benefits: The steady deposit mobilization supported a favorable liability mix, keeping the overall cost of funds on a downward trajectory at 6.86% for the quarter. Accelerated Non-MFI Asset Diversification: Secured loans expanded 42.7% YoY to constitute 50.4% of the total book, keeping the bank on track for its 56% secured mix target by FY27-end. High-Margin Growth Engines: Emerging portfolios saw rapid scaling: Gold loans jumped 248.1% YoY, Vehicle loans rose 85.1% YoY, and MSME Agri loans grew 68.6% YoY. Improving Asset Quality & Reduced Slippages: Bank-level GNPA dropped 10 bps QoQ to 2.17% with a strong 85% PCR, supported by annualized MFI slippages dropping to 1.72% (down from 2.68% in Q4 FY26). Upgraded Guidance for Profitability & Asset Quality: Management raised its FY27 ROA guidance to 1.8%-2.0% and lowered credit cost expectations to 0.9%-1.0% of average total assets. Operational Efficiency Cushion: The management optimized full-year OPEX guidance downward to ~6.4% of average assets, even after factoring in ₹250 crore in planned capacity building and branch additions. Could the re-rating be finally on the cards? 2. Privi Speciality Chemicals Privi posted yet another good quarter living up to it's consistent compounder tag! Management is confident of maintaining a 20% revenue CAGR with 24-25% EBITDA margins. FY27 Growth Triggers Phase 1 capacity expansion: 48,000 MT → 54,000 MT by September 2026, with current utilization already at ~90% Merger completion: Consolidation of Privi Fine Sciences and Biotechnologies adds ~6,000 MT capacity and operational synergies by FY27 year-end Givaudan JV scaling: JV turned profitable in Q4 FY26 (₹18 crores revenue with an EBITDA margin of 14-15%); additional ₹50 crore equity infusion planned for next phase of 42 products FY28 Growth Triggers Phase 2 capacity expansion: 54,000 MT → 66,000 MT by September 2027, adding 12,000 MT of flagship product capacity New specialty products commercialization: Maltol, Ethyl Maltol, Musk T, Cyclopentanone and 10+ specialty molecules coming online by H2 FY28, furfural vertical alone targets ₹1,000+ crore revenue Backward integration moat: Only global player fully integrated from corn cob to maltol/ethyl maltol, capturing China+1 demand as 95%+ supply currently comes from China 3. Gravita India If one has a preference for value buys, Gravita could present an interesting opportunity over the next month or two! Near Term challenges Scrap supply disruption: 15-20% of imports from Gulf remain stuck due to Middle East war; Q2 will still see some impact Low lead volumes: First YoY decline in lead volumes seen in Q1; recovery depends on supply normalization High working capital: 95-day cycle and INR 150cr net debt due to copper inventory and transit stock Copper utilization stuck at ~50%: Debottlenecking only by end-FY27, so near-term margins diluted Growth Triggers for H2FY27 & FY28 Own scrap yards in US/developed nations: Setting up now; operational by year-end to replace Gulf dependency and cut costs Copper debottlenecking + new Gujarat plant: Utilization to hit 60%+ by Q4FY27; EBITDA/ton to rise from INR 55k to 60k by year-end, 70-75k over 2-3 years Lead capacity utilization recovery: Phagi and Mundra expansions at ~45-50% now; to reach ~70% as scrap flows normalize Copper capacity doubling: From ~30k to 60k MTPA over next 3 years via organic expansion LME brand listing for lead: Opens global OEM doors and export opportunities Value-added product mix: Already at 63% (from 45%); even ex-copper improved to ~50%, supporting margins Lithium-ion battery recycling: R&D for full value chain (not just black mass); refining unit planned as volumes scale Strong balance sheet: AA rating, capex fully funded by internal accruals; no equity dilution risk 4. Ramkrishna Forgings After going thru multiple struggles for several quarters, RK Forgings has delivered back to back good quarters with good growth and margin expansion. Management claims they are on track to hit 8000 crore revenues by FY29 and that essentially means a 23-25% CAGR for the next three years. Management also assured that company should see continued improvement in terms of margin every quarter from now onwards. In the previous earnings cycle, company used to operate at 21-22% margins and that's perhaps would be the first target to reach. Company is planning to reduce debt by at least ₹500 crore in FY27 and that should directly flow into PAT! The company is targeting an ROCE of 12-15% in FY27 and 20% in FY28 (it was in single digits last two financial years) So where is the growth coming from? Exports: Management stated that FY27 could be one of the best years in export revenue Mexico Plant: Contributed ₹6 crore revenue in Q1 and but expected to clock significant numbers from Q3 FY27 Railway & Wheel JV: Trial production has already started, expected to submit the samples to Indian railways in August, and management is hoping to start Bulk by September or October 2026. Future Growth Trigger: Company has commenced bulk supplies of aluminum forgings, marking non-ferrous products as its next major growth lever. Management is aggressively expanding into aluminum, stainless steel, Inconel, and other advanced alloys for aerospace, semiconductors, and robotics, with meaningful revenue contribution expected over the next 12–24 months. 5. ACCs and Battery chemicals Recently Nuvama published an interesting read about Battery Chemicals and here is the short summary of it: Advanced Chemistry Cells (ACC): Next-generation rechargeable battery cells, including Lithium-ion (LFP, NMC, LMFP, NCA), Sodium-ion, Solid-state, and other advanced chemistries. Today, lithium-ion accounts for more than 95% of global ACC demand. India ACC demand to grow at 39% CAGR during 2025-30E and the demand would grow at 27% CAGR during 2030-35E; EV battery demand to grow at 35% CAGR during FY25-30; BESS is likely to see a 78% CAGR during FY25-30 (although supply seems to be low as of now). India is transitioning from being primarily an importer of battery materials to developing a domestic battery chemicals ecosystem. The Government launched the ₹18,100 crore PLI Scheme for ACC Batteries to establish 50 GWh of domestic cell manufacturing capacity. In addition, over 10 manufacturers have announced around 178 GWh of battery manufacturing capacity, creating significant downstream demand for battery chemicals. Cathode materials alone account for roughly 35–45% of battery cost, with anode and electrolyte adding another 20–25% combined. Key Indian players Neogen Chemicals: Electrolytes, Electrolyte salts (LupF6), electrolyte additives Himadri Speciality: Synthetic graphite, silicon-carbon anodes, LFP cathode materials Gujarat Fluorochemicals: LiPF₆(electrolyte salt), Electrolyte formulations & additives, LFP Cathode Active Material (CAM), PVDF & PTFE battery binders, Next-generation anode materials Tatva Chintan Pharma Chem: Electrolyte additives and specialty chemicals Sudeep Pharma: Battery-grade iron phosphate and other derivatives for Cathode Active Material (CAM) That's all for this edition. Have a great Sunday! Disclaimer: None or buy or sell recommendations. This publicly available information is shared for learning and education purposes.
17
37
2
394
47,322
Budding_Trader retweeted
Timepass talk on Sunday 1. X-Men: Days of Future Past Ramkrishna Forgings: "...I can only assure you that you will see continued improvement in terms of margin every quarter now..." Tips Music: "...we get approximately 15% of our revenue from the content which are released over the last three years and the balance 85% is spread across let's say the past three decades..." Sterlite Technologies: "...ConCat is redefining US FTTX deployment economics for new builds, expansions, and overbuilds. This slashes labor costs by up to 71% and by eliminating field splicing and reducing reliance on skilled labor..." Note - FTTX (Fiber To The X) refers to the deployment of fiber-optic cables to deliver high-speed internet, replacing older copper-based networks, with variants like FTTH (Fiber to the Home) or Fiber to the Building (FTTB) representing the fastest, most direct connections. In the United States, FTTX expansion is being driven by BEAD (Broadband Equity, Access, and Deployment), a $42.45 billion federal program aimed at bringing high-speed internet to unserved and underserved areas. Acutaas: "...we have successfully completed the trial run of our battery chemicals plant and started commercial supplies. Demand here is unprecedented given by tight global supplies..." Meesho: "...for more than 50% of our sellers, let's say, we would be a primary source of income..." Ujjivan Small Finance Bank: "...our progress towards diversification of loan portfolio remains on track, with more than half of the loan book being secured at 50.4% as of June 26..." Sona BLW Precision: "...Our ambition over the next decade is simple, we want to build another 10x company..." 2. OneSource Specialty Pharma OneSource Specialty Pharma is a integrated, multi-modality specialty pharmaceutical CDMO company, focused on developing and manufacturing Drug Device Combinations (DDC), biologics, sterile injectables and oral technologies such as soft gelatin capsules. The company remains firmly on track toward its FY28 guidance of 3600-3800 Crore ($400 million) in organic revenue and 40% EBITDA margins. If OneSource does achieve that, it would now be trading at 13x FY28 EV/EBITDA! The company’s growth is being propelled by two major pillars. First, its drug device combination (DDC) business is gaining significant commercial momentum, particularly in GLP-1 therapies like Semaglutide. In Canada, the world’s largest off-patent market, all three available approvals are partnered with OneSource, with two already launched, while in India the company manufactures over 40% of generic pens sold. With a second cartridge line set for commercialization in Q2FY27, a third line expected within FY27, and a fourth later in FY28, the company is scaling from 225 to over 675 sterile days to meet surging demand across existing and new markets. Second, biologics is emerging as a long-term driver, underscored by the recent partnership with Formycon and a rapidly expanding RFP funnel that is nearly four times larger than a year ago. While biologics revenues today are largely from development and MSAs, commercial contributions are expected to ramp meaningfully from FY29 onward, supported by planned expansions in both mammalian and microbial capacity. Company has gone thru 12 successful regulatory and customer audits in Q1 alone, including two surprise FDA inspections! Company claims that despite a temporary supply disruption from Dr. Reddy's, all capacities remain full due to a multiple client base. Company has added 6 new customers and 9 new launches in Q1. 3. Laurus Labs The latest concall was particularly refreshing, with management clearly articulating Laurus Labs' long-term vision. The company reiterated that its strategy is to evolve into a fully integrated pharmaceutical company with end-to-end capabilities across the pharmaceutical value chain, spanning from APIs to finished drug products. This integrated approach encompasses its generics, CDMO, and New Chemical Entity (NCE) businesses. While much of the industry remains focused on expanding capabilities in key starting materials (KSMs) and APIs, Laurus Labs is already laying the foundation for what the pharmaceutical landscape could look like by 2030. With CDMO contributing 43% of total revenue, Laurus Labs appears to have reached a significant milestone in its business transformation. While it remains important to monitor the next two to three quarters to assess whether a 40%+ CDMO revenue share is sustainable, the company already seems to be well ahead of its stated objective of deriving 50% of its revenue from CDMO by 2030. capex guidance for FY27 started at ₹1,000 Cr, raised to ₹1,500 Cr and now guided at ₹2,000 Cr for FY27! And this isn't speculative capacity plan, it's "based on what our customer demands are". Laurus isn't just riding the small-molecule wave. They are deliberately building capabilities in: ADCs: Development and commercial agreement with Arvik Therapeutics for two preclinical ADC molecules (India market), plus payload-linker programs for big pharma Gene Therapy: Licensed patents from IIT Kanpur, investment in ImmunoAct for lentiviral/cell therapy understanding Peptides: Multiple classes beyond just GLP-1 weight-loss drugs; commercial-scale synthesizers being qualified With management focused on improving asset turnover to above 1.0x and gradually driving ROCE toward 25%, Laurus Labs appears to be laying the foundation for a well-rounded pharmaceutical giant. The execution roadmap is clearly defined; the rest will depend on the company's ability to deliver consistently over the coming years. Investors now have an opportunity to observe and witness that transformation unfold. 4. Weight loss and Diabetes drugs Novo Nordisk and Eli Lilly are expected to dominate the global weight management drug market in 2026, together accounting for an estimated 87% of prescription weight-loss drug revenues. Industry estimates suggest the global weight-loss drug market could reach approximately $65 billion in 2026 and expand to nearly $195 billion by 2035. Of course, by then, several key GLP-1 patents are likely to have expired, creating a significant opportunity for generic manufacturers to capture a meaningful share of this rapidly expanding market. Eli Lilly is getting ready to file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as the treatment succeeds in two more late-stage trials. Dubbed the "triple G" drug, retatrutide targets GLP-1, GIP and glucagon rather than just one or two of those hormones like existing treatments. What is Triple G? Human body naturally makes several hormones that control hunger, blood sugar, and metabolism. Three of the big ones are: GLP-1 (glucagon-like peptide-1): Released after you eat, tells your brain "I am full," slows down digestion, and helps your body release insulin to manage blood sugar. GIP (glucose-dependent insulinotropic polypeptide): Another gut hormone that also helps control insulin and blood sugar, and seems to play a role in fat metabolism. Glucagon: This one's a bit different. It normally raises blood sugar (it's kind of GLP-1's opposite in that sense), but it also increases the rate your body burns energy (your metabolic rate) and burns fat. What existing drugs do? Older drugs like Ozempic/Wegovy (semaglutide) only target GLP-1. That's "one hormone." Newer drugs like Mounjaro/Zepbound (tirzepatide) target both GLP-1 and GIP. That's "two hormones" — this is why tirzepatide tends to produce more weight loss than semaglutide alone. What retatrutide does? It's designed to activate all three receptors, GLP-1, GIP, and glucagon, at once. That's the "triple G" (three hormones). Why that matters (in theory at least)? The GLP-1 and GIP parts help reduce appetite and improve blood sugar control, just like existing drugs. The added glucagon activation is the new piece, it may boost how many calories your body burns, on top of just eating less. Think of it like this - Existing drugs mostly work by turning down your hunger dial. Retatrutide tries to turn down the hunger dial and turn up the "calorie-burning engine" dial at the same time, theoretically a more powerful combination, which is part of why it's shown very high weight-loss numbers in trials so far. Within our market context, Divi's and Sai Life are supposed to be connected to Eli Lilly's weight loss programs 5. Anthem Biosciences Anthem displayed the inherent lumpiness of the CDMO business this past quarter. Q1FY27 revenue declined roughly 25% YoY as key customers deferred deliveries to later quarters, making it the softest quarter of the year. The weakness was broad-based across CRDMO and specialty ingredients, with Unit 2 utilization falling to ~50% and management flagging temporary demand rebalancing and supply-chain pressures. However, the stock price didn't decline as much as one would have expected given the results. Here is why: Industry-leading margins: Despite the revenue decline, the company delivered year-on-year margin expansion as management continued to improve cost efficiencies through flow chemistry, biocatalysis, and backward integration, reinforcing profitability. Strong revenue visibility and sticky client base: The company entered the year with ~60% of its full-year order book already in hand, including a newly onboarded big pharma client and deepening engagements (R&D + commercial) with existing global customers. Multi-year capacity-driven growth runway: Unit 3 (New Anthem) utilization is ramping from ~15% to 30–35%, while Unit 4 (365 KL custom synthesis + 100 KL fermentation) is under construction and targeted for commissioning by end-FY28, providing a clear path to volume expansion. Exposure to high-growth modalities: Anthem is building capabilities in next-generation areas such as ADCs, peptides, and GLP-1 (semaglutide API awaiting CDSCO approval), positioning it to capture long-term demand from innovators and domestic generic players. Fortress balance sheet funding aggressive capex: Net cash stood at ₹1,720 crore as of June 2026, comfortably supporting the ~₹1,200 crore Unit 4 capex outlay without balance-sheet stress; working capital remains stable. Resilient, long-term business model: Despite quarterly lumpiness from customer delivery schedules, the CRDMO model is highly regulated and "sticky," with customer relationships spanning years and four recently commercialized molecules beginning to contribute to a growing annuity-like revenue stream. Of course, Anthem is by no means cheap and certainly isn't trading at a reasonable valuation. However, the valuation of many CDMO companies is a topic for another day! That's all for this edition. Have a great Sunday! Disclaimer: None or buy or sell recommendations. This publicly available information is shared for learning and education purposes.
19
68
4
483
61,578
Budding_Trader retweeted
#shilpamedicate #concordbiotech The Patent Cliff Is Coming — Here's What It Means for Your Pharma Portfolio If you invest in Indian pharma stocks, there's one story you should understand right now: a wave of the world's best-selling drugs is about to lose patent protection. When that happens, cheaper copies (generics and biosimilars) flood in, prices crash, and someone has to make all those cheaper copies. That "someone" is very often an Indian company. This is called a patent cliff. It's happened before, but the one coming between 2025 and 2030 is the biggest in over a decade. Here's what's expiring, who stands to gain, and — importantly — which smaller, less obvious companies are also in the game. First, the size of the prize Roughly ₹22–23 lakh crore worth of drug sales (in the US market alone) are set to lose patent protection between 2025 and 2030. Just the top 20 drugs on that list are worth about ₹16.9 lakh crore a year today. Indian companies won't capture all of that — most estimates say India could realistically capture around ₹29,000–48,000 crore a year once you account for how much prices collapse after a patent expires. That's still a meaningful, multi-year growth opportunity for the sector. The drugs going off patent (and why they matter) Keytruda (Merck) is the world's best-selling drug, bringing in roughly ₹2.8–3.1 lakh crore a year treating various cancers. Its core US patent is expected to expire around 2028. Because it's a biologic — a complex protein, not a simple chemical pill — copying it requires a "biosimilar," which is far harder and costlier to develop than a regular generic. Eliquis (Bristol Myers Squibb / Pfizer) is a blood thinner doing around ₹1.15 lakh crore a year. Generic versions are expected in the US from around 2028. Being a simple pill, it should be much easier and faster for generic makers to copy once the door opens. Stelara (Johnson & Johnson) treats immune conditions like psoriasis and Crohn's disease, worth about ₹96,000 crore a year. Biosimilar competition has already begun since 2025. Opdivo (Bristol Myers Squibb) is another major cancer immunotherapy, at roughly ₹86,000 crore a year, expected to lose US protection around 2028–29. Like Keytruda, it's a biologic. Xarelto (J&J / Bayer), a blood thinner worth about ₹67,000 crore a year, faces US patent expiry around 2026 — one of the more closely watched pill-based cliffs. Farxiga (AstraZeneca), used for diabetes and kidney disease, does roughly ₹67,000–74,000 crore a year, with key patents starting to lapse from 2025. Entresto (Novartis), a heart-failure drug worth about ₹58,000 crore a year, already saw its first US generics launch in July 2025. Ibrance (Pfizer), a breast cancer pill worth ₹52,000–61,000 crore a year, is expected to face generic competition around 2027. Enbrel (Amgen / Pfizer), an immune-disease biologic worth about ₹52,000 crore a year, is expected to lose protection around 2028. Prolia/Xgeva (Amgen), used for bone health, brings in ₹38,000 crore-plus a year; its US patent already expired in 2025 and biosimilars are launching. Januvia/Janumet (Merck), diabetes pills worth ₹21,000–36,000 crore combined, lose protection in 2026. Why the "pill vs. biologic" distinction matters: simple pills (Eliquis, Xarelto, Entresto, Ibrance, Farxiga) are easy for Indian generic companies to copy — that's the business they've done for 20+ years. Biologics (Keytruda, Stelara, Opdivo, Enbrel, Prolia) are complex proteins grown in living cells — copying them ("biosimilars") is much harder, much more expensive, and only a handful of Indian companies can actually do it. That difference matters when you're deciding which stock is a "safe, obvious" beneficiary versus a "harder, higher-payoff" bet. The large caps everyone already knows about If you follow pharma investing, these names will sound familiar as the "usual suspects" for this theme: Biocon — India's most established biosimilar player, already selling multiple biosimilars globally, roughly a fifth of the US insulin glargine market. Dr. Reddy's Laboratories — has partnered with Alvotech to develop biosimilars for both Keytruda and Prolia/Xgeva. Zydus Lifesciences — has licensed a pembrolizumab (Keytruda) biosimilar candidate and is racing to be an early filer. Cipla — investing heavily in biosimilar R&D, plus a strong existing US generics business. Sun Pharma — India's largest pharma company, a potential contender in the Keytruda biosimilar race. Aurobindo Pharma — doubled its biosimilar R&D budget, has a large US generics/injectables base. Lupin — building out its own biosimilar pipeline alongside complex generics. Torrent Pharmaceuticals — was among the first to launch a generic version of Entresto in the US. Natco Pharma — known for winning tough, litigation-heavy "first-to-file" generic opportunities, especially in oncology. These are the names that show up in every analyst note on this theme. If you want simple, liquid, well-covered exposure to the patent cliff, this is where most investors start. The less obvious part: small and micro-cap names This is where it gets more interesting — and riskier. Most of the coverage on this theme focuses on the big names above. But a few smaller companies are directly involved, and some are actually named in company announcements and analyst calls. Shilpa Medicare — the clearest small-cap story here.Shilpa Medicare is officially classified as a small-cap stock (around ₹11,000–12,000 crore market cap). Its subsidiary, Shilpa Biologicals, just signed a deal with Finland's Orion to co-develop and supply a biosimilar version of Opdivo (nivolumab) for Europe — Opdivo being one of the exact drugs on our patent-cliff list above (~₹86,000 crore in annual sales). This isn't a vague "we're exploring biosimilars" statement — it's a named molecule, a named partner, and a named market. That makes Shilpa one of the few small-cap stocks with a specific, real bet on this exact theme, not just thematic exposure. Concord Biotech — the "picks and shovels" small cap.Also SEBI-classified as small cap (~₹11,000–14,000 crore). Concord makes fermentation-based APIs (the raw ingredients) used in immunosuppressant and oncology drugs. It doesn't own a branded biosimilar itself, but brokerage Antique Stock Broking recently resumed coverage with a "buy" rating, specifically pointing to the 2026–2028 patent cliff (around 90 drugs, worth roughly ₹5.1 lakh crore) as a long-term tailwind for domestic-focused generic ingredient makers like Concord. A few mid-caps worth knowing (bigger than "small cap," but still smaller than Sun Pharma/Cipla-scale names): Neuland Laboratories (~₹23,000–25,000 crore) — management has openly called GLP-1 peptide manufacturing (used for diabetes/weight-loss drugs going off patent) a "key growth driver," and is building a dedicated commercial peptide facility for it. Sai Life Sciences — a contract manufacturer whose management has confirmed on an earnings call that it has "clinical assets in the GLP-1 space." Anthem Biosciences — went public in 2025 and has since grown into large-cap territory, but PL Capital (Prabhudas Lilladher), which initiated coverage with a "BUY," specifically flagged its specialty ingredients business benefiting from a GLP-1 API ramp-up from the second half of CY26, alongside biosimilar launches, as named growth drivers. Why you won't find many true micro-caps here If you were hoping to find a tiny, under-the-radar stock with huge upside on this theme — that's genuinely hard to find, and here's why: making a biosimilar costs roughly ₹100–150 crore per molecule and requires specialized biologics manufacturing know-how. That's simply out of reach for most very small companies. So at the smallest end of the market, the real exposure usually comes through supplying ingredients or manufacturing capacity to the bigger players — not through a tiny company owning its own branded biosimilar. Shilpa Medicare is the exception that proves the rule, and even it required years of investment to get there. What this means for an investor 1. The opportunity is real, but it's not evenly spread. Simple-pill generics (Eliquis, Xarelto, Entresto-type drugs) are lower-risk, lower-reward — almost any decent generic company can make these. Biosimilars (Keytruda, Stelara, Opdivo-type drugs) are higher-risk, higher-reward — only a few companies can actually pull them off, but the payoff is bigger if they do. 2. Big names = safer, more diversified exposure. Biocon, Dr. Reddy's, Cipla, Sun Pharma, and peers are unlikely to "blow up" your portfolio, but they also won't 10x on this theme alone — it's one growth driver among many for a large, diversified business 3. Smaller names = concentrated, higher-conviction bets. Shilpa Medicare's Opdivo biosimilar deal, or Concord Biotech's ingredient-supply tailwind, are the kind of bets where a single deal or launch matters a lot more to the stock price — which cuts both ways. 4. Patents don't just expire on schedule — companies fight to delay them. Merck alone has reportedly filed around 300 patents around Keytruda to push out competition. Litigation, patent extensions, and settlements can delay these dates by years. Don't assume the calendar dates above are locked in. 5. Biosimilar sales don't collapse to zero overnight the way pill generics do. Doctors and patients switch to biosimilars more slowly than they switch to a generic pill, so even a "successful" biosimilar launch takes longer to show up in a company's revenue. Bottom line The 2025–2030 patent cliff is one of the more durable, multi-year growth stories in Indian pharma — real demand, real numbers, and real company-level evidence (deals, concall commentary, capacity build-outs) backing it up. The big names give you steady, diversified exposure. Shilpa Medicare and Concord Biotech give you smaller, more concentrated ways to play the same theme, with more company-specific risk attached. Either way, this is a theme worth tracking company announcements and quarterly concalls for — because the winners here will be decided by execution, not just being in the right sector. [Not investment advice, DYOR]
25
106
2
522
47,968
Budding_Trader retweeted
Timepass talk on Sunday 1. Wires, Cables & Optical Fiber: The Data Centre Gold Rush India's data centre build-out is creating a massive opportunity for both conventional cables and optical fiber. Polycab, in its latest concall, stated: "We estimate that 1 MW translates into around ₹3.5 crore worth of cables, with 50–60% being conventional cables and the balance being optical fiber." In fact, KEI's management made a similar observation a few months ago. Several industry estimates suggest that India's data centre capacity could increase nearly 5x to ~8 GW by 2030. That implies a total cable opportunity of around ₹28,000 crore, comprising: • Conventional cables (50–60%): ₹14,000–16,800 crore • Optical fiber cables (40–50%): ₹11,200–14,000 crore The data centre story isn't just about servers, GPUs and power infrastructure. It is also a long-duration demand driver for wires, cables and optical fiber. Polycab also said: "We've read reports where the estimation is somewhere around 8 gigawatt to 16 gigawatt or 18 gigawatt" Wires, Cables & Optical Fiber - Lage Raho Munna Bhai. 2. Transmission Infrastructure Enters Hypergrowth Phase India plans to more than double its installed electricity generation capacity to 1,121 GW by FY36, implying the addition of nearly 600 GW over the current installed base of around 530 GW. Roughly 70% (786 GW) of this capacity is expected to come from non-fossil fuel sources. But renewable energy alone isn't enough. To address the intermittency of solar and wind power, India also plans to deploy 174 GW of energy storage capacity, comprising 80 GW of Battery Energy Storage Systems (BESS) and 94 GW of Pumped Storage Projects (PSP). Now comes the most important question: How will all this electricity reach consumers? The answer lies in transmission infrastructure. Polycab's latest concall was a goldmine of information on this theme. Management highlighted that transmission line additions averaged around 15,000 circuit kilometres per year during FY20-FY25. They now expect this pace to accelerate to 20,000-21,000 circuit kilometres annually over FY26-FY30, a 35-40% increase in the rate of grid expansion. They also pointed to the Central Electricity Authority's target of at least 17,000 circuit kilometres for the current financial year. Execution appears to be off to a strong start, with nearly 2,000 circuit kilometres commissioned in April and May alone, while June data is yet to be released. This is precisely what makes the transmission theme compelling. India recently exempted four Chinese-linked power equipment makers from prior bidding curbs, allowing them into government T&D tenders for two years. This move directly corroborates this thesis. However, the biggest beneficiaries may not be the entire sector. Returns could be concentrated among high-voltage equipment players and import substitution players, so choose your winners wisely. I am personally tracking, Yash Highvoltage, Hindusthan Insulators, Quality Power, KSH International, Atlanta Electricals and TARIL but valuation comfort is missing in most of these names. 3. Triveni Power Transmission (shared on June 7th) Triveni Engineering’s Power Transmission Business (PTB), focused on high-speed gears, industrial gearboxes, and defense propulsion systems, is arguably one of the hidden gems within Triveni Engineering & Industries. The business is expected to be listed before the end of August 2026. The NCLT has already approved the demerger, and the record date is likely to be announced by the end of this month, give or take a few days. With EBITDA margins of around 35%, a strong and diversified customer base, a sticky business model supported by a growing aftermarket segment, and a dedicated multi-modal defense manufacturing facility, PTB appears well-positioned for the next phase of growth. Capacity expansion is currently underway, with the potential to take revenues from FY26 levels of ₹340 crore to a peak capacity of around ₹700 crore over time. The company has also secured a significant breakthrough order in the defense segment recently, further strengthening its growth visibility. Another interesting aspect is its Swiss subsidiary, which could emerge as a wildcard. Located in Schaffhausen, Switzerland, a renowned precision engineering and industrial manufacturing hub bordering Germany, it provides PTB with proximity to several leading European OEMs and strategic access to key export markets. The aftermarket business continues to gain importance. Its contribution to overall gear revenues increased to 40% in FY26, compared to a historical average of just over 30%. Triveni's turnaround time for standard aftermarket solutions is typically 2-3 months, versus an estimated 12 months for some global competitors. To further strengthen this advantage, the company has commissioned a dedicated aftermarket facility in Mysore aimed at improving execution speed and reducing delivery timelines for international customers. Overall, PTB appears to be entering an interesting phase with multiple growth levers in place. It is certainly a business worth keeping on the watchlist once the standalone listing takes place. Latest update: July 22, 2026 is the record date for the demerger. Shareholders of Triveni Engineering will receive 1 equity share of Triveni Power Transmission Limited (face value: ₹2 each) for every 3 equity shares of Triveni Engineering held on the record date. 4. Menon Bearings (shared on Jan 25th) Menon Bearings delivered one of the strongest quarters in its history. Exports rose to an all-time high of ~36% of revenues, notably without any adverse impact from US tariffs. In its recent concall, management noted: “…we have already started additional business with one of the major customers from the US… we hardly see any impact from the tariffs imposed by the USA. On the contrary, our exports are poised to grow further going ahead...” For a company of this size, this is an interesting and positive development, especially in a challenging global environment. That said, management also acknowledged that elevated copper prices are a margin headwind. While the company claims a pass-through mechanism, the timing and completeness of quarterly/monthly pass-throughs remain an open variable and need close monitoring. From a cautionary standpoint, it’s worth recalling that in 2023 the company had articulated an ambition to double revenues by FY26. At the current run rate, the company appears far from that target, and it no longer seems to be a stated objective in the latest investor deck. Nevertheless, a company executing well amid headwinds deserves a closer look. Latest Update: Since then, the company has delivered two consecutive quarters of strong performance, with EBITDA margins exceeding 20%, and the stock is now trading at an all-time high. The FY27 revenue guidance of ₹360 crore now appears conservative. Railway Opportunity: A new dynamometer is expected by August-end, which will enable entry into the Indian Railways segment. Menon Alkop (Aluminium): The share of EV business is currently 4-5% and is targeted to reach 8-10% by the end of FY27. North America Focus: A recent visit to the USA & Canada is expected to generate an additional ₹65-75 crores in business over the current and next financial year. New Customer Pipeline: Already receiving RFQs and signing NDAs with major auto players like Magna, Linamar, and Allison Transmission. These concall snippets are courtesy of @concall_in who do excellent job in compiling concall notes for most companies with super fast speed! Disc: I have no association or financial obligations with @concall_in. 5. GSM Foils GSM Foils is a seven (7) year old pharma packaging company that makes aluminium blister and strip foils used for tablets and capsules. These foils protect medicines from moisture, oxygen, and contamination, ensuring patient safety. The company has over 100+ clients spread across 14+ states in India, with a strong reputation for quality and customization. Most of their customers are tier-3 and tier-4 pharma companies who are cost conscious but still need high quality products. They have more clients than the employees! It's a two product company that manufacturers Blister Foils (~65%) and Aluminum Strip Pharma Foils (~35%). The company operates an asset-light business model, with fixed assets of just ~₹5 crore, while consistently delivering 11–12% EBITDA margins. Management is targeting a monthly revenue run rate of ₹60 crore by March 2027, implying FY27 revenue of ₹400–450 crore. The growth trajectory is already visible: Q1 FY27 revenue: ~₹97 crore (vs. ~₹52 crore in Q1 FY26 and ~₹82 crore in Q4 FY26) Profit nearly doubled YoY, reflecting strong operating leverage. The previous quarter was impacted by a sharp rise in aluminium and ethyl acetate prices, but the company appears to have navigated those headwinds well, with margins recovering. Another positive is management's increasing focus on transparency, with monthly business updates now being shared regularly. While the company has historically faced challenges around receivables and working capital, management has taken steps to mitigate these issues. Nevertheless, given its small size, some of these challenges may continue to persist as the company aims to grow faster. That is something investors need to keep an eye on. That's all for this edition. Have a great Sunday! Disclaimer: None or buy or sell recommendations. This publicly available information is shared for learning and education purposes.
22
58
2
451
65,608
Budding_Trader retweeted
Timepass talk on Sunday This week, let's revisit some of the names we've discussed before and focus on the key things to watch for in their Q1 results. 1. Rishabh Instruments - Shared on Feb 8, 2026 I presented Rishabh Instruments at ALD event when the stock price was in the ₹200s. My conviction was based largely on management’s stated target of ~₹100 Cr EBITDA for FY26. Now, looking at 9M FY26, EBITDA has already crossed ~₹93 Cr, a clear sign the management is walking the talk on restoring profitability. This improvement wasn’t accidental. It also involved consciously cutting low-margin/non-profitable revenues, especially from Lumel Alucast (automotive segment). While Electrical & Electronic Instrumentation remains the primary growth driver, the company has finally sounded positive on its solar business. After a long period of losses, the segment has turned operating-level profitable and the company has secured fresh orders for its single-phase inverter models. FY27 could become an important year for this vertical. However, profitability recovery is only step one. The bigger trigger will be growth. Currently the growth engine is still running a bit slow, the day revenue growth starts sustaining ~20–25%, the probability of a re-rating increases meaningfully. Management teams that go through tough conditions and fix their business models deserve attention. Execution during adversity often tells you more than execution during tailwinds. Current update: They delivered an EBITDA of ₹126 crore in FY26, exceeding their guidance. The stock price naturally reflected that performance. What to track in Q1 commentary: How is the U.S. market growing? How are the rest of the international markets shaping up? How fast is the solar inverter business growing? How is the EMS business progressing? And how is Lumel Alucast's (die-casting) profitability shaping up? 2. Sakar Health - Shared on Feb 8, 2026 Sakar Health post fantastic results in Q3FY26 and concall is coming up on Feb 11th. Founded in 2004, Sakar has evolved from a small contract manufacturer into an API-integrated pharmaceutical company with a growing global presence. The company now operates WHO-GMP and EU-GMP approved facilities in Gujarat, exports to 60+ countries, and has built a portfolio of ~292 product registrations across 75 international partners. They operate in three verticals: 1. CDMO / CMO Services, 2. Own Brand Exports, 3. Licensing / Product Development. For most of its history Sakar was primarily a generic formulations exporter, but in the last few years it has pivoted meaningfully toward oncology, and that is increasingly becoming the real story. The company has set up a vertically integrated oncology facility with EU-GMP approval. Its oncology portfolio includes 55 in-house developed products, of which 32 are ready for global launch. It has already secured 11 Marketing Authorisations (MAs) across geographies (six in Europe and the balance across APAC and Latin America). On the CDMO/CMO side, Sakar manufactures for established Indian pharma companies such as Zydus Life Sciences, Torrent Pharmaceuticals, Indus Pharma, Emcure, Cipla and Glenmark, with ~20 active clients. Going forward, while their generic formulations unit would continue to grow steadily (primarily in export markets), the two growth engines will be the CMO for these big Indian MNCs and Oncology portfolio. If execution sustains, Sakar appears to be transitioning from a plain export-generic company into a specialty manufacturing + oncology platform, which is a very different valuation narrative. Current Update: Sakar posted a solid Q4 and a guided for a promising FY27 What to track in Q1 commentary? Management has guided for approximately ₹200 crore in oncology sales for FY27 (vs. ~₹96 crore in FY26). Q1 should provide the first indication of whether the company is on track to achieve this target. Management expects around 25 of the 31 EU dossiers to be commercialized by Q3 FY27. Q1 should ideally reflect the initial commercialization of the first few dossiers. Capacity utilization at the Bavla oncology facility will also be a key metric to monitor. 3. RBZ Jewellers - Shared on March 8, 2026 RBZ Jewellers operates a unique dual-channel model, combining a strong B2B wholesale presence, supplying to national giants like Titan, Malabar and PNG, with its high-growth B2C retail brand, Harit Zaveri Jewellers, which currently operates an ~11,000 sq. ft. flagship store in Ahmedabad. A little over a year ago, RBZ had guided for ₹800 crore revenue in FY26 and ₹1,000 crore in FY27. During the Q4FY25 concall, the FY26 guidance was moderated to ₹700 crore, while FY27 guidance of ₹1,000 crore was retained. However, in the Q3FY26 concall, management further revised expectations, guiding for ₹630–650 crore in FY26 and ₹800–900 crore in FY27. With multiple factors coming together (guidance coming down, volumes coming down), the market seems to have lost interest in the stock, pushing valuations to what appears to be their cheapest levels so far. But there may be a silver lining. The company is on track to open two large retail stores in Surat and Rajkot by Q2FY27. If executed well, these three stores could potentially push retail revenues into four digits, while also improving overall margins. That said, in the near term PAT may remain under pressure, as marketing spends and other launch-related expenses could weigh on profitability in FY27. Structurally, the business mix is also evolving. By FY27, volumes are expected to be roughly split 50:50 between retail and B2B, while retail could contribute ~75% of revenues, with wholesale and job work accounting for the remaining ~25%. Current update: Posted decent Q4 What to track in Q1: Progress in the launch of new stores. Inventory and working capital trends. Promotional spending for newly launched stores and its impact on profitability. Progress of the daily wear product launch. Effectiveness of the company's hedging strategy in managing input cost volatility and protecting margins. 4. KSH International - Shared on March 15, 2026 KSH International is a specialized industrial player focused on magnet winding wires and Continuously Transposed Conductors (CTC), high-precision components that are critical for large power transformers, EV traction motors, and generators. You might ask: there are many companies riding the electrification theme, so why look at this one? Here are a few reasons: i) KSH is the third-largest manufacturer of magnet winding wires in India and the largest exporter of the same, supplying to 24+ countries. Being an approved vendor for global utilities and OEMs is a high-entry-barrier business, built over years of qualification and trust. ii) The company serves global heavyweights such as Hitachi Energy, GE Vernova, Toshiba, and Siemens Energy, along with Indian giants like Power Grid, NTPC, and BHEL. It also holds RDSO approval and supplies to several Indian transformer manufacturers. Roughly 40–45% of revenues come from power transformers, grid infrastructure, and HVDC/EHV transformers, making KSH a strong proxy for the broader electrification theme. iii) While other major players such as Precision Wires India and Apar Industries manufacture CTC and winding wires, KSH International is currently the only Indian company approved and certified to supply CTC specifically for 400kV HVDC transformers. HVDC transformers operate under extreme electrical stress; even a minor defect in the CTC winding can trigger catastrophic grid failures, which is why micron-level precision is critical. iv) The company has added significant capacity over the last six months, taking total annualized capacity to 43,445 MT. This is expected to increase further to 59,045 MT by FY27, providing a clear runway for volume-led growth. The expanded capacity also positions the company well to pursue opportunities in export markets. v) With better margins than peers, a near-monopoly position in HVDC CTC, capacity expansion underway, and strong tailwinds from the electrification theme, KSH appears to sit in a favorable strategic position. Of course, valuations may not necessarily be cheap, and that is ultimately a call each investor needs to make. Current Update: Lived up to the hype and capped off FY26 with a strong Q4 performance. What to track in Q1? Consolidated utilization was at ~70% in Q4FY26. How did Q1 do, particularly Supa plant utilization? EBITDA/ton sustainability in the range of INR 68,000 and 74,000 in Q4 Export momentum trending towards 40% target? Any progress on Q4 commentary of "...some of our large transformer clients have also begun to explore long-term multi-year agreements..." Progress on PEEK and green copper backward integration 5. India’s CDMO Inflection Point - FY27; Shared on March 29, 2026 Clearly, India’s CDMO opportunity is still much smaller than China’s, but relative to where we were a few years ago, the ecosystem has evolved meaningfully. FY27–FY28 could well turn out to be the scale years for the sector. Acutaas: Guided for ~₹1,000 crore CDMO revenue by FY28, with four products validated in FY26 expected to start contributing to the topline from FY27, providing clear visibility into the next phase of growth. In parallel, the company has taken a strategic step into semiconductor chemicals, specifically raw materials for photoresists, through its South Korea acquisition, adding a new high-growth vertical to the business. That said, the stock has seen a sharp run-up recently and may not offer the most attractive entry point at current valuations. Navin Fluorine: CDMO revenues of ₹360 crore in 9MFY26, with a target of ₹850–880 crore (~$100 million) by FY27. The company has a pipeline of 10–15 molecules. Beyond CDMO, multiple capacities in other verticals are expected to go live in FY27 offering strong earnings uptick! Sai Life Sciences: Manufacturing capacity to expand from ~700 KL in FY26 to 925 KL by Q1FY27 and 1,150 KL by Q4FY27 (≈65% increase). Added 7 molecules in FY26 (3 commercial, 4 in Phase III). Sai will be the primary supplier in two of these molecules . They are expected to sustain the margins in the range of 28% to 30%. Divi’s Laboratories: Three large dedicated projects under execution, with commercial volumes expected from H2CY27. Over 18 MT peptide capacity, including Tirzepatide and potentially Orforglipron post regulatory approvals. GLP molecules are expected to add significant growth! Laurus Labs: Barring a few logistical disruptions stemming from the Iran conflict, the company is expected to deliver a strong Q4 and maintain healthy growth in FY27 over FY26. Valuations may not appear cheap, but as the saying goes, value ultimately lies in the eye of the beholder. Current Update: All of these companies appear to be on track with their CDMO journey. Acutaas lived up to the hype, Laurus guided for 30% EBITDA margins, and Sai Life nearly doubled its capex plans between FY26 and FY27. That said, Sai Life's commercialization timeline appears to have been pushed back slightly compared to its original guidance. What to track: Management commentary on additional molecules. Capacity utilization trends across key facilities. Impact of raw material inflation on margins. Progress of ongoing capex and commercialization timelines. Drivers of margin improvement and sustainability of profitability. That's all for this edition. Have a great Sunday! Disclaimer: None or buy or sell recommendations. This publicly available information is shared for learning and education purposes.
16
62
2
405
60,005
Budding_Trader retweeted
Timepass talk on Sunday 1. Apollo Micro Systems Defence Acquisition Council approved ₹52,000 crore worth military purchase that includes: • Anti-Unmanned Aerial Vehicles (UAV) Electronic Warfare System • Man Portable Anti-Tank Guided Missile (MPATGM) • Medium Range Surface-to-Air Missile (MRSAM) weapon system • Very Short Range Air Defence System (V-SHORADS) • Active Protection Systems for tanks • Jet-powered kamikaze drones • Multi Influence Ground Mine (MIGM) • Naval Shipborne Unmanned Aerial System (NSUAS) In these, one line-item is directly connected to Apollo Micro - Multi Influence Ground Mine (MIGM) The MIGM is a "smart," high-tech underwater weapon indigenously designed by the DRDO's Naval Science & Technological Laboratory (NSTL) based in Visakhapatnam to target enemy warships and submarines. The Tech: Traditional sea mines are "dumb" and detonate on contact or proximity, risking friendly ships. The MIGM is programmable and passively listens for unique target signatures. It uses multiple sensors to track acoustic, magnetic, pressure, Underwater Electric Potential (UEP), and Extra Low Frequency Electric Field (ELFE) signatures before deciding to detonate. The BDL & Apollo Micro Connection: Both Bharat Dynamics Limited (BDL) and Apollo Micro Systems (AMS) are the chosen production partners for this technology. Apollo Micro Systems received the technology transfer for the MIGM-Vighana variant and acts as a Development-cum-Production Partner (DcPP). Additionally, industry chatter suggests that Bharat Electronics (BEL) is close to securing a ₹30,000 crore Quick Reaction Surface-to-Air Missile (QRSAM) order—a programme in which Apollo Micro Systems supplies the Integrated Avionics Unit (IAU) and Actuator. On top of that, the market has been abuzz with speculation that the company could be evaluating the acquisition of another defence player. Of course, the stock is trading at an all-time high, and valuations are also hovering near record levels. 2. Dixon-Vivo JV The market is abuzz with expectations that the Dixon–Vivo JV will soon receive government approval. The proposed joint venture (JV) between Dixon Technologies and Vivo is a massive structural catalyst. It dramatically changes Dixon's scale, moving them from a pure third-party contract manufacturer to a controlling partner in one of India's largest smartphone ecosystems Dixon will hold a 51% majority stake, while Vivo India will retain 49%. Vivo sold an estimated 3.5 crore handsets in India in 2025. For comparison, Dixon’s entire standalone mobile production volume for the same period hovered around 3.2 crore units. Brokerage estimates (such as JPMorgan and JM Financial) indicate that roughly 60% to 67% of Vivo India’s annual volumes will transition into this JV structure. This means an incremental addition of 2.2 to 2.4 crore units annually at peak run rate, practically expanding Dixon's total smartphone handling capability by over 60–70%. Dixon closed the FY26 fiscal year with a total revenue of ₹48,873 crore (with the mobile and EMS vertical contributing ₹44,257 crore). Management guidance has indicated that the Vivo JV opens up a ₹30,000 crore revenue opportunity. If and when the government grants its approval, the stock may witness a quick run-up. 3. Gabriel India Mahindra & Mahindra (M&M): M&M's passenger vehicle business delivered a strong 15% YoY growth in Q1FY27 volumes, with cumulative sales reaching 1,74,745 units. The momentum continues to be driven by its domestic utility vehicle portfolio, which touched a milestone of 60,393 units in June alone (up 28% YoY), supported by expanding production capacity and sustained demand for the Scorpio, Thar, and XUV range. TVS Motor: TVS reported its highest-ever quarterly sales of 16.31 lakh units, up 27% YoY, driven by broad-based growth across both domestic and export markets. The biggest highlight, however, was the phenomenal performance of its electric two-wheeler business. EV sales crossed 1.30 lakh units during the quarter, while June EV volumes alone surged an astonishing 237% YoY, underscoring the company's rapidly strengthening position in India's electric mobility market. Maruti Suzuki India: Maruti continued its dominance, with Q1FY27 retail registrations rising 27.3% YoY to 4,98,632 units. Now you're probably thinking... "Did I put the wrong heading?" No, I didn't. Here's why all of this matters for Gabriel India. More than 60% of Gabriel India's revenue comes from the 2W and 3W segment, where TVS Motor is its largest customer. Gabriel also commands an impressive 32% market share in this segment. Another 24% of revenue comes from the passenger vehicle (PV) segment, where Maruti Suzuki and M&M are its two largest customers. I'll leave the math to you. Sometimes, the best way to analyze an auto ancillary is to first study its customers 4. Marine Electricals (India) Limited (Blast from the past) From Jan’26 till date, the company has secured ~₹1163 Cr of orders (ex-tax). While the bulk continues to come from its core power distribution systems business, it is encouraging to see incremental orders from data centres and semiconductor facilities, indicating early diversification. Most of these orders are to be executed within ~12-18 months, providing near-term revenue visibility. Already a silent proxy to naval spending, Marine is also building optional growth drivers such as EV charging solutions, though these are still at a nascent stage. On the defence side, the company already has capabilities in shock-graded motors and electrical systems, designed to withstand extreme naval conditions (including underwater shocks), creating high entry barriers and sticky relationships. That said, naval revenues have historically been lumpy, given long project cycles and execution timelines. Importantly, the Indian Navy plans to scale its fleet to 150–160 ships by 2030, 200+ by 2035, and ~230 by 2037, reflecting a clear long-term expansion roadmap. With multiple vessels under parallel construction, this could translate into a more consistent order pipeline for established players like Marine Electricals over the coming years. Only drawback: Marine Electricals Limited doesn’t conduct concalls, making it relatively difficult for investors to track developments and management commentary. 5. OnEMI Technology Solutions (Kissht) Kissht operates as a technology company doing lending! Lets start with the Q1FY27 update Q1FY27 Provisional Business Update: On July 4, 2026, the company posted a strong provisional update, with AUM surging 60.9% YoY (and 13.2% QoQ) to cross the ₹8,001 crore mark. Quarterly disbursements grew 37.1% YoY to ₹3,812 crore, its registered user base expanded to 74.6 million, and the secured LAP portfolio mix further diversified upward to 7.7% of total AUM. Are these just one-off eye-popping numbers? Lets look at what they did in FY26 Robust Scale & Premium Return Profile (FY26): Kissht crossed a critical milestone with Assets Under Management (AUM) growing 73% YoY to ₹7,066 crore, delivering a stellar 75% YoY increase in Profit After Tax (PAT) to ₹281 crore. This rapid scaling is backed by best-in-class profitability metrics, reflecting a Return on Average AUM (RoAAUM) of 5.05% and a Return on Average Equity (RoAE) of 23.97%. Advanced AI Underwriting Edge: Moving beyond rigid traditional bureau data, the company's proprietary underwriting engine analyzes over 60 million registered users across 7,000+ granular variables. The graduation to complex transformer-based AI sequence models has driven its Area Under the Curve (AUC) risk metric to 74% in 2026, delivering roughly 2.5x better risk separation than conventional bureau frameworks. Sharply Improving Asset Quality: Gross NPA (Stage 3) contracted significantly by 77 basis points YoY to 2.12%, while Net NPA was tightly contained at 0.29%. This improvement is underpinned by a highly conservative provisioning stance, raising Stage 2 ECL coverage to 75.6% alongside a ₹136 crore management overlay to insulate the book from unexpected macro shocks. Margin Optimization & Lower Cost of Funds: The company has intentionally shifted focus toward higher-quality, lower-yielding borrower cohorts, structurally lowering its overall impairment costs as a percentage of AUM from 9.7% in FY25 to 8.2% in FY26. Concurrently, its newly assigned CRISIL/India Ratings A- / Stable rating has chopped ~200 bps off marginal borrowing costs. Secured LAP Diversification & Organic Sourcing: To de-risk its unsecured digital credit book, Kissht scaled its secured Loan Against Property (LAP) segment to ₹518 crore across 98 branches. This expansion is highly margin-acquisitive, with over 40% of LAP customers being directly cross-sold from the existing captive database, drastically lowering customer acquisition costs (CAC). That's all for this edition. Have a great Sunday! Disclaimer: None or buy or sell recommendations. This publicly available information is shared for learning and education purposes.
29
73
9
624
112,680